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Inorganic arsenic, an established toxicant, has been associated with numerous 
health outcomes, including cancer of the lung. Evidence on the impact of arsenic 
exposure on nonmalignant respiratory outcomes, however, is less conclusive as studies 
examining low-moderate levels (<50 µg/L) of water arsenic exposure are limited. In the 
US, elevated arsenic disproportionately affects populations relying on private well water, 
including many American Indian communities. Additionally, these communities have 
historically been at an increased risk of tuberculosis. This dissertation aimed to better 
understand the relationships between arsenic exposure and nonmalignant respiratory 
health outcomes in a population exposed to low-moderate arsenic from drinking water. 
We used data from the Strong Heart Study (SHS), a prospective cohort of American 
Indian adults, and the Strong Heart Water Study (SHWS), a randomized controlled trial 
aiming to reduce arsenic exposure in American Indian communities. 
First, we conducted an analysis in 2,132 SHS participants to evaluate associations 
of arsenic exposure with lung health using urinary arsenic measurements at baseline 
(1989-1991) and spirometric measurements at Visit 2 (1993-1995). Arsenic exposure was 
positively associated with restrictive pattern, airflow obstruction, lower lung function, 
self-reported emphysema and having to stop for breath, independent of smoking and 
other lung disease risk factors. 
Second, we evaluated the relationship between a history of active tuberculosis and 
subsequent lung function in 2,463 SHS participants. We observed that a history of active 
tuberculosis was associated with airflow obstruction, restrictive pattern, and respiratory 
symptoms. We found a reduced odds of tuberculosis with increasing arsenic exposure, 
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contrary to our hypothesis, but suggestive evidence of a possible synergistic interaction 
between arsenic and tuberculosis on worse lung function.  
Third, we conducted a pilot study, in preparation for the SHWS, of 371 
households to identify households with arsenic ≥10 µg/L. Arsenic ≥10 µg/L was found in 
26.1% of households and median water arsenic concentration was 6.3 µg/L, ranging from 
<1 to 198 µg/L. The study also tested and confirmed the effectiveness of a water filtration 
device to reduce water arsenic in these communities. The long-term efficacy of a 
community-based arsenic mitigation program in reducing arsenic exposure and 
preventing arsenic related disease is being tested as part of the SHWS.   
In conclusion, low-moderate arsenic exposure may contribute to nonmalignant 
respiratory outcomes, including reduced lung function, respiratory symptoms, and a 
restrictive lung disease pattern. Our findings support existing knowledge that tuberculosis 
is a risk factor for long-term respiratory impairment. There is a relatively high burden of 
arsenic exposure in communities where the SHWS is being conducted, pointing to the 
continued need for effective interventions at the household level. More research is needed 
to investigate the association between arsenic exposure and non-malignant respiratory 
health, as many populations at risk of developing tuberculosis and other respiratory 
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This dissertation is the final result of the research work conducted with my co-
advisors, co-authors, and collaborators during my doctoral studies in the Department of 
Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public 
Health. This dissertation is organized in a manuscript format. First, we present our 
specific aims and then provide an overview of, and the motivations behind, this 
dissertation. We then review each of the analyses conducted, organized into three 
chapters. The first chapter evaluates the association between arsenic exposure with 
nonmalignant respiratory outcomes in the Strong Heart Study. The second chapter 
evaluates the association between a history of active tuberculosis and subsequent lung 
health, as well as the potential association between tuberculosis and arsenic exposure, in 
the Strong Heart Study. The third chapter evaluates the results of a water quality pilot 
study conducted for the Strong Heart Water Study. Finally, the discussion provides an 
overview of the research findings, strengths and limitations to the analyses, implications 
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Chronic respiratory diseases represent a major health burden around the globe, 
affecting hundreds of millions of people and resulting in four million premature deaths 
annually.1 Chronic diseases of the airways represent a wide array of serious diseases, 
such as lung cancer, lung fibrosis, and chronic obstructive pulmonary disease, which 
includes bronchitis and emphysema.2 In the United States (US), chronic obstructive 
pulmonary disease continues to be a leading cause of morbidity and mortality,3 and 
restrictive disease is associated with a fair or poor self-reported health status.4 
Respiratory disease is frequently avoidable, with prevention often costing a fraction of 
treatment.1 Tobacco smoke, exposure to indoor and outdoor air pollutants, allergens, and 
occupational exposures are important modifiable risk factors of chronic respiratory 
diseases,5 but there is need for research to identify relevant environmental factors that are 
less well established, especially as chronic respiratory disease is increasing in 
prevalence.1, 2  
The role of arsenic, an established toxicant and carcinogen, through ingestion 
from drinking water on lung cancer risk is well established, with the International Agency 
for Research on Cancer classifying arsenic in drinking water as a type 1 lung 
carcinogen.6, 7 However, evidence on the impact of arsenic exposure on nonmalignant 
outcomes, such as lung function and exacerbation of respiratory symptoms, is less 
conclusive. Existing evidence supports an association between arsenic exposure with 
lung function, respiratory symptoms, lower respiratory infections, bronchiectasis, and 
tuberculosis;8-10 however, most studies are in populations exposed to higher arsenic levels 
in drinking water (>50 µg/L).11-26 A recent systematic review showed strong evidence of 
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a general association between arsenic and nonmalignant respiratory diseases at high 
levels of arsenic exposure,24 but the evidence base is in need of additional prospective 
studies, especially at low-moderate levels (<50 µg/L) of arsenic exposure. Further, few 
studies conducted in the US have investigated the association between arsenic and 
respiratory health.15, 16, 27 
Elevated exposure to arsenic disproportionately affects populations relying on 
private well water in the US. Rural and suburban families relying on ground water, 
including many in American Indian communities, are the most affected, especially in 
portions of the Southwest, Midwest and Northeast US. 28 Private wells do not fall under 
the jurisdiction of the US Environmental Protection Agency’s Safe Drinking Water Act, 
and it is the responsibility of the well owner to make sure their water is safe. Major 
barriers to arsenic water testing exist, including general awareness and lack of access to 
water testing.29 In American Indians who participated in the Strong Heart Study, a 
population-based study ongoing since 1988 comprised of tribal members from 
Oklahoma, Arizona, North Dakota, and South Dakota, elevated exposure arsenic from 
private well water has been associated with numerous health outcomes30-33 including 
increased mortality for lung cancer.33 Additionally, these same communities historically 
have been at an increased risk of tuberculosis due to a higher than average prevalence of 
predisposing risk factors, such as diabetes, smoking, and socioeconomic circumstances.34 
Little is known about the nonmalignant respiratory health outcomes in this population, 
either associated with a past history of tuberculosis, which is commonly associated with 
long-term pulmonary damage,35 or chronic arsenic exposure, both of which could 
potentially be contributing to an unmeasured burden of chronic lung disease. 
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Additionally, minority groups, including American Indians, are underrepresented in 
published biomedical and clinical research on pulmonary disease,36 further pointing to the 
need to investigate the group’s respiratory health. 
The main objectives of this dissertation were to (1) evaluate the relationship 
between arsenic exposure and nonmalignant respiratory health in a population chronically 
exposed to low-moderate arsenic levels; (2) evaluate the impact of tuberculosis survival 
on lung function and its potential association with arsenic exposure in the Strong Heart 
Study; and (3) conduct water arsenic testing and a water quality assessment pilot for the 
Strong Heart Water Study intervention, aimed at reducing water arsenic at the household 
level to improve health outcomes. 
 
The hypotheses of this dissertation were: 
1)  In the Strong Heart Study population, a US population chronically exposed to low-
moderate arsenic levels through drinking water, lung function is reduced and respiratory 
symptoms are increased, independent of smoking status and dependent on arsenic levels. 
2) In the Strong Heart Study population, a history of active tuberculosis and subsequent 
recovery is associated with consequent reduced lung function and increased respiratory 
symptoms. Elevated arsenic levels are associated with an increased odds of a past history 
of active tuberculosis. Elevated arsenic levels and history of active tuberculosis 
synergistically interact on reduced lung function and increased respiratory symptoms.  
3) In the Strong Heart Water Study setting of low-moderate arsenic levels, arsenic above the 
maximum contaminant level of ≥10 µg/L in drinking water is common, and a selected 
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point-of-use adsorptive media filter, for use in the intervention, will be effective at 
reducing arsenic levels and providing arsenic safe water for drinking and cooking.  
 
 To test these hypotheses, we used data from the Strong Heart Study (SHS), a 
population-based prospective cohort study designed to investigate cardiovascular disease, 
diabetes and their risk factors in American Indians, as well as the Strong Heart Water 
Study (SHWS), a randomized controlled trial intervention that delivers a water arsenic 
removal device at the household level, designed to include SHS members. The SHS and 
SHWS serve as ideal populations to understand the relationship between low-moderate 
arsenic exposure and respiratory outcomes given widespread exposure to arsenic through 
drinking water and the availability of multiple measures of respiratory health status. 
 
The specific aims were the following: 
Aim 1: To evaluate the association of arsenic exposure with lung function and respiratory 
health using collected SHS data. To complete this aim, we conducted an analysis using 
urinary arsenic measurements at baseline (1989-1991) and spirometry measures, self-
reported respiratory symptoms, and self-reported respiratory nonmalignant disease at 
Visit 2 (1993-1995) from 2,132 participants. 
 
Aim 2: To evaluate the impact of active tuberculosis survival on lung health in an 
historically highly impacted population of American Indians. We conducted an analysis 
using tuberculosis data and spirometry measures from the Visit 2 examination (1993 – 
1995) in 2,463 individuals. In an additional analysis, we evaluated the potential 
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association between a history of active tuberculosis and arsenic exposure and their 
possible interaction on lung disease. 
 
Aim 3: To identify households with private wells with elevated arsenic that are eligible 
for the SHWS, using inductive coupled plasma mass spectrometry vs. a rapid arsenic 
screening tool, and to assess the efficacy of a selected point-of-use adsorptive media filter 
and water quality parameters that could interfere with the efficacy of the filter. To 
complete this aim, we conducted a pilot study where 371 households were tested for 
arsenic ≥10 µg/L between 2014 – 2018. A more detailed water quality assessment was 
performed in 29 of these households. 
 
Nonmalignant respiratory disease can have a profound negative effect on quality 
of life.37 Efforts to understand environmental risk factors are critical, as is understanding 
the implications of arsenic at low-moderate exposure levels on respiratory health, 
particularly as it is an understudied health effect. With SHS participants continually 
affected by exposure to arsenic, especially those on private well water, the need for an 
effective intervention at the household level is necessary. This dissertation provides a 
thorough investigation into the association between arsenic exposure and nonmalignant 
respiratory health, presenting evidence to support future arsenic health effects prevention 








 In this chapter we review the existing literature on the following topics: (1) lung 
health in American Indian communities; (2) epidemiological evidence on arsenic induced 
patterns of respiratory disease; (3) experimental evidence on arsenic exposure with 
respiratory disease; (4) factors affecting lung health; and (5) diabetes as a sensitivity 
analysis. 
 
Lung Health in American Indian Communities 
In comparison to the general US population, American Indians and Alaska Natives, 
comprised of an estimated 2.3 million individuals who identified themselves in 2008 
solely as such,1 have increased rates of infectious lung diseases and lower rates of 
smoking-related diseases.2 At the time the Strong Heart Study Phase II was taking place 
(1993-1995), the most prominent respiratory diseases in American Indian adults were 
pneumonia, lung cancer, chronic obstructive pulmonary disease, and tuberculosis.3 
Historically, a low prevalence of asthma has been reported in the American Indian 
population,3 but in the SHS, underdiagnosis of asthma has been a concern, as 4% of 
participants in the SHS’s third examination (1998-1999) had probable but previously 
undiagnosed asthma.4 Limited information is available on the occurrence of chronic 
obstructive pulmonary disease (COPD) among American Indians, but the mortality rate 
was approximately one-third compared to the rate for all races in the US (years 1984 – 
1988), although mortality studies based on death certificate data are well known to 
7 
 
severely underestimate the burden of disease in American Indian communities. Mortality 
rates for COPD were lower among American Indians in the Southwest, where smoking 
rates are lower, as compared to rates for American Indians of the Great Plains, where 
smoking is common.2  Similarly, lung cancer mortality rates for American Indians are 
much higher in north central states as compared to the southwest due to much higher 
smoking rates. However, even in the north central states, where the rates of smoking 
exceed those of the rest of the population, the rates of deaths from lung cancer are only 
just slightly more than one-half the rate for all races in the US. Tuberculosis, even as 
incidence among American Indians has declined, remains disproportionately high when 
compared to incidence among the white population.2 Possible reasons for increased 
mortality from tuberculosis include diabetes incidence, poverty and socioeconomic 
conditions, smoking, and alcohol use.2 Individuals with diabetes from the Oglala Sioux 
Tribe were 5.2 times more likely to progress to active tuberculosis disease than non-
diabetic individuals with a positive tuberculin test.5  Additionally, Indian Health Service 
facilities often have been understaffed, particularly in North/South Dakota, resulting in 
tuberculosis preventative measures being postponed to deal with more urgent 
emergencies.5 
 
Epidemiological Evidence on Arsenic Induced Patterns of Respiratory Disease 
Spirometry is a frequently used method for assessing lung function.6 The main 
parameters used to assess lung function include: the forced expiratory volume in one 
second (FEV1), the forced vital capacity (FVC), and forced expiratory ratio 
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(FEV1/FVC). While spirometry does not diagnose lung disease, different patterns of 
spirometry can identify specific abnormalities associated with certain lung diseases and 
can be classified as obstructive or restrictive. Obstructive diseases, like chronic 
obstructive pulmonary disease, an umbrella term used to describe progressive lung 
diseases including emphysema and chronic bronchitis, are characterized by persistent 
airflow limitations, breathlessness, and a reduced FEV1/FVC and FEV1 with a preserved 
FVC.7 Major risk factors include smoking, occupational exposures, and air pollution. 
Asthma is another obstructive lung disease that can have reversible, intermittent, or 
permanent changes in spirometric lung function measurements. Restrictive pulmonary 
abnormalities, characterized by a reduced FEV1 and FVC with a stable or higher 
FEV1/FVC, result in a decreased total lung capacity as a result of reduced lung 
compliance.7, 8 Restrictive lung impairment can be intrinsic, resulting from inflammation 
or scarring of lung tissue as a result of disease like pulmonary fibrosis, or extrinsic, 
resulting from disorders affecting respiratory muscle function, such as scoliosis and 
muscular dystrophy.8 Major risk factors include diabetes, waist circumference, smoking, 
and occupational exposures. An obstructive pattern of lung impairment is found in 
approximately 13.6% of US adults, and restrictive impairment is found in 6.5%, with 
only minimal changes found when comparing rates from 1988-1994 and 2007-2010, 
indicating an enduring disease burden.9 In addition, lung diseases have been found to be 
associated with repeat hospitalizations, higher health care costs, and poor quality of life.9-
11  
FEV1 and FVC. Across the body of evidence from general populations exposed 
to arsenic in drinking water, increasing arsenic exposure was associated with a decline in 
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lung function.12 Several studies from arsenic-endemic areas in South Asia reported lower 
FEV1 and FVC among study participants with very high levels of arsenic in drinking 
water (>250 µg/L).13, 14 A study from India investigating the impact of low-moderate 
arsenic exposure on lung function found that those exposed to 11-50 µg/L compared to 
<10 µg/L had 500 mL lower mean FVC (p< 0.001), as well as lower FEV1.15 In a meta-
analysis of nine studies with water arsenic levels ranging from 23 to 860 µg/L, arsenic 
exposure was associated with lower FEV1 and FVC.16 In a recent study from the US, no 
association was seen with arsenic exposure and lung function.17 
FEV1/FVC ratio. In a recent meta-analysis which excluded studies where arsenic 
skin lesions were the only exposure marker,16 only three studies reported effects 
estimates for the FEV1/FVC ratio,13, 18, 19 for which the meta-analysis found no evidence 
of an association, suggestive of restrictive lung deficits. A large population study in 
Bangladesh found inverse but not statistically significant associations between arsenic 
exposures measured in urine or water with FEV1/FVC, however the data were not 
shown.20 In a recent study examining NHANES data with individual spirometry 
measurements and urinary arsenic, no significant association was found in relation to 
FEV1/FVC ratio.17 
Strong Heart Study spirometry reference values. At the time of the SHS Visit 2 
(1993-1995), reference equations derived from a sample of the general US population 
from the National Health and Nutrition Examination Study (NHANES) III did not 
include American Indians.21 Marion et. al used data from the Strong Heart Study to 
derive normative values for the SHS. In order to have reliable reference values used for 
the prediction of lung function, the reference cohort should be representative and free of 
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factors interfering with the results;22 the reference group used to derive SHS normative 
values excluded individuals with variables that were significant predictors of FEV1, 
including cigarette smoking >10 pack-years, asthma or wheezing, diabetes, or indexes of 
obesity.  
Respiratory symptoms. A systematic review examined eighteen publications 
investigating the relationship between arsenic and respiratory symptoms.12 The studies 
reported anywhere from one to nineteen different symptom-related endpoints, either 
individually or combined. Results have been mixed, with some studies finding 
statistically significant positive associations between arsenic and at least one respiratory 
symptom,15, 23-30 while others found no significant association between arsenic levels and 
any respiratory symptom assessed.13, 14, 18, 31-33  
Respiratory disease. Only a small number of studies have examined chronic 
bronchitis, emphysema, and asthma with arsenic exposure; as a result, the relationship 
between arsenic and specific chronic nonmalignant lung disease is not clear.12 A study 
from the US reported a greater odds of self-reported emphysema among those with the 
highest quartile of arsenic exposure (>17.23 µg/L) compared to those in the lowest 
quartile (<3.52 µg/L), but results were not statistically significant (OR=1.29, 95% 
CI=0.17, 9.82).33 The study also reported those in the highest quartile of exposure had 
lower odds of self-reported chronic bronchitis compared to those in the lowest quartile, 
but results did not achieve statistical significant after adjustments (OR=0.77, 95% 
CI=0.24, 2.51). The direction of this finding is inconsistent with three other studies on 
chronic bronchitis, two of which found increased odds of chronic bronchitis in those with 
arsenical skin lesions.14, 31, 34 For asthma, no increase in mortality was identified in an 
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arsenic-exposed region in Taiwan,35 and in the US population, a reduced odds of asthma 
was found, but the results were not statistically significant (OR=0.71, 95% CI=0.41, 
1.24).33 
 
Experimental Evidence on Arsenic Exposure with Respiratory Disease 
 Despite epidemiologic evidence, little is known regarding arsenic-induced effects 
on airway physiology; 36, 37 although a number of studies have shown that arsenic is 
deposited in the lung, particularly in the epithelium.38 Results of epidemiological studies 
have suggested that arsenic exposure is linked to chronic loss of lung defenses, including 
the secretion of clara cell secretory protein (CC16), a protein that plays major role in 
protecting alveolar epithelium from pollutants, from airway cells.24, 38  
In mice, exposure of low to moderate concentrations of arsenic in drinking water 
(10 – 100 ppb) led to a decrease in immune gene expression and aberration in 
inflammatory protein expression.39, 40 As a result, mice were more susceptible to airway 
inflammation.41 Other mice studies suggest genes which sustain wound repair, lung 
matrix, and barrier function are comprised with arsenic exposure.42-44 Increased 
expression of matrix metalloproteinase-9 (MMP-9), a matrix degradation enzyme, might 
be an important biomarker of the inhibitory effect of arsenic on lung function.45, 46 In 
confluent human airway epithelial cells, arsenic increased time to close a scratch wound; 
this reduced wound repair was associated with increased expression of MMP-9 activity.47 
Airway remodeling is a hallmark of a number of respiratory diseases; changes in 
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expression and organization of extracellular matrix genes and in expression of mediators 
and enzymes that control matrix remodeling have consistently been observed.47  
 
Factors Impacting Lung Health 
Reference values for spirometry are based on the most important anthropometric 
factors of height, age, sex, and race. Historically, age has been a major factor when 
examining the lung, as lung function begins to decline after reaching pulmonary maturity 
at about 20-25 years of age.48 The lung is affected by advancing age by impairment in 
respiratory mechanics, including rigidity of the chest wall, decreased diameter of small 
airways, and decreased elastic recoil of the lung.49 There is debate over whether the 
diagnostic thresholds that define spirometric obstruction are adequate for age-related 
changes. The Global Initiative for Obstructive Lung Disease (GOLD) threshold of <0.70 
for FEV1/FVC is thought to often misclassify normal spirometry as airflow obstruction in 
non-smokers, particularly in older adults.50 The American Thoracic Society recommends 
using the lower limit of normal (LLN) instead of the fixed GOLD ratio. The LLN is 
statistically defined by the lower 5th percentile of a reference population, calculated by 
subtracting 1.64 times the standard deviation from the mean (expected value).51 However, 
it is likely that the LLN misses individuals with mild airflow obstruction,51 and 
underdiagnosis of obstruction may be a larger problem than overdiagnosis.52 
Height also affects lung function measurements. Taller individuals have greater 
lung capacity, so their lung volume will decrease at a greater rate compared to shorter 
individuals as they age. Among individuals of the same weight and height, men have 
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larger lungs than women, resulting in a larger number on bronchi and greater alveolar 
surface area. Men tend to have higher airflow values than women, but FEV1 decreases 
with age more rapidly in men than in women due to respiratory muscle strength 
decreasing more significantly in men.48 
There are many factors that are relevant to lung health in certain cases that are not 
taken into account by reference standards, including lifestyle factors and environmental 
exposures. Tobacco smoking in adults is a well-established risk factor for lung disease, 
including acceleration of age-related decline in lung function and increased respiratory 
symptoms.53 Body mass index can affect pulmonary physiology, influencing breathing 
pattern and respiratory mechanics.54 Indoor air pollution related to biomass fuel, such as 
heating with an open fireplace in developed countries, has been associated with lung 
disease including COPD, risk of developing pulmonary tuberculosis, and faster decline in 
lung function.55 Outdoor air pollutants like particulate matter have been shown to affect 
chronic lung health, with a possible significant association between particulate matter 
concentrations and the rate of age-related decline in FEV1.56 
 
Diabetes as a Sensitivity Analysis 
In Chapter 1, when examining the association between lung health and arsenic, 
we conducted sensitivity analyses by further adjusting models for diabetes. Diabetes was 
treated as a sensitivity analysis; the temporal and causal relationship between diabetes 
and lung function is debated. Cross-sectional studies have found that individuals with 
diabetes often have reduced lung function compared to those without diabetes,57-59 but the 
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definitive direction in addition to the pathophysiological mechanism to explain the 
association between lung function and diabetes is not known.60 A cross-sectional study of 
older individuals without a history of chronic lung disease found duration of diabetes to 
be associated with reduced lung function, suggesting diabetes duration influences lung 
function more than glycemic control, and that obesity may also contribute.61 In a large 
longitudinal study (N= 27,711), a low FEV1 preceded and significantly predicted future 
diabetes, with the relationship not fully explained by inflammation, smoking, or 
obesity.62 There is likely a complex model of diabetes-related lung damage;61 proposed 
mechanisms for the relationship between reduced lung function and diabetes include 
chronic inflammation, microangiopathy of lung vasculature, and loss of elastic recoil due 
to glycosylation of lung parenchyma.62 With consideration to the body of research 
examining arsenic exposure and lung function, previous studies have not adjusted for 
diabetes.12 The SHS population has a high rate of diabetes, with prevalence close to 
50%,63 and impaired lung function has been found to present before the development of 
diabetes.64 Additionally, there is a large body of evidence suggesting that chronic arsenic 
exposure can contribute to diabetes development, further pointing to the need for a 
sensitivity analysis in our evaluation of the relationship between arsenic and lung health 
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Background: Arsenic exposure through drinking water is an established lung 
carcinogen. Evidence on non-malignant lung outcomes is less conclusive and suggests 
arsenic is associated with lower lung function. Studies examining low-moderate arsenic 
exposure (<50 µg/L), the level relevant for most populations, are limited. We evaluated 
the association of arsenic exposure with respiratory health in American Indians from the 
Northern Plains, the Southern Plains and the Southwest United States, communities with 
environmental exposure to inorganic arsenic through drinking water. 
Methods: The Strong Heart Study is a prospective study of American Indian adults. This 
analysis used urinary arsenic measurements at baseline (1989-1991) and spirometry at 
Visit 2 (1993-1995) from 2,132 participants to evaluate associations of arsenic exposure 
with airflow obstruction, restrictive pattern, self-reported respiratory disease, and 
symptoms. 
Results: Airflow obstruction was present in 21.5% and restrictive pattern was present in 
14.4%. The odds ratio (95% confidence interval) for obstruction and restrictive patterns, 
based on the fixed ratio definition, comparing the 75th to 25th percentile of arsenic, was 
1.17 (0.99, 1.38) and 1.27 (1.01, 1.60), respectively, after adjustments, and 1.28 (1.02, 
1.60) and 1.33 (0.90, 1.50), respectively, based on the lower limit of normal definition. 
Arsenic was associated with lower percent predicted FEV1 and FVC, self-reported 
emphysema and stopping for breath. 
Conclusions: Low-moderate arsenic exposure was positively associated with restrictive 
pattern, airflow obstruction, lower lung function, self-reported emphysema and stopping 
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for breath, independent of smoking and other lung disease risk factors. Findings suggest 





















Arsenic exposure via drinking water is a well-established lung carcinogen 1-3. 
More recently, water arsenic >100 µg/L has been associated with non-malignant 
respiratory effects, including respiratory symptoms and worse lung function tests. A 
recent meta-analysis identified an association between arsenic exposure and reduced 
forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) with a 
preserved ratio (in subset of 3 studies reporting FEV1/FVC), indicating a possible 
association with restrictive lung disease 4. The studies in the meta-analysis included a 
wide range of exposure levels, with arsenic often ten times higher than the World Health 
Organization guideline/United States Environmental Protection Agency standard of 10 
g/L in drinking water. More evidence is needed regarding the risks associated with low-
moderate levels of arsenic exposure (<50 µg/L), and levels common in the US and other 
countries (<10 µg/L). A recent systematic review showed strong evidence of an 
association between high levels of arsenic exposure with respiratory symptoms, non-
malignant respiratory illness, and reduced lung function 5. One study from the US found 
no association between low-moderate arsenic exposure and self-reported diagnosis or 
symptoms of obstructive lung disease but lacked spirometry data 6. We examined the 
association of low-moderate arsenic exposure with respiratory health in American Indians 
from the Northern Plains, the Southern Plains and the Southwest United States, 






The Strong Heart Study (SHS) is an ongoing population-based, prospective study 
of cardiovascular disease and its risk factors in American Indian adults. The SHS 
recruited 4,549 residents of Tribal Nations from study sites located in Arizona (AZ), 
Oklahoma (OK), and North Dakota and South Dakota (ND/SD) in the US. Study 
enrollment rates were 71.8% in AZ, 61.5% in OK, and 55.3% in ND/SD 7. All men and 
women aged 45 to 74 years at the baseline visit in 1989-1991 were invited to participate, 
with subsequent clinical visits 8. In 2016, one community in Arizona withdrew their 
consent, reducing the cohort to 3,516 participants. To account for the unintended 
withdrawal of a Tribal Nation, all analyses were weighted using inverse probability 
weighting. As study site proportion is known from the original cohort, the withdrawal of 
the Tribal Nation was adjusted for by weighting the remaining participants, with 
approximately 1/3 of weight for each center (33.0% AZ, 33.6% OK, 33.4% ND/SD); the 
use of the statistical weight is to reduce bias introduced by drop-out 9.  
This study used urinary arsenic data from the baseline examination and 
spirometry from Visit 2 (1993-1995), both available in 2,271 participants. We excluded 
94 participants missing baseline data on smoking status and cigarette pack-years, 11 
missing diabetes status, education, or body mass index (BMI), and 34 missing 
tuberculosis data, leaving 2,132 participants for our analyses.  
 
Data collection 
Visits included biospecimen collection, physical exam, and an interviewer-
administered standardized questionnaire. Visits were performed by trained and certified 





Morning spot urine samples were collected at baseline 8. For arsenic analyses, 
urine concentrations of inorganic arsenic (iAs), methylarsonate (MMA), and 
dimethylarsinate (DMA) were measured using high performance liquid 
chromatography/inductively coupled plasma-mass spectrometry. The metabolism of 
inorganic arsenic in the human body results in MMA and DMA which are excreted in 
urine together with unchanged inorganic arsenic. Quality control and assurance methods 
and laboratory procedures for urine analysis have been previously described 10. We used 
the sum of inorganic and methylated arsenic species (iAs+MMA+DMA) as the 
biomarker of exposure to inorganic arsenic in drinking water and food. Arsenobetaine 
levels are low in the population (median (10th, 90th percentiles): 0.5 µg/g (<0.6 – 6.10) 
creatinine], confirming that seafood intake is rare 11. Urine arsenic concentrations (µg/L) 
were divided by urine creatinine concentrations (g/L) to account for urine dilution in spot 
urine samples and expressed as concentrations of total urine arsenic and its species in 
µg/g creatinine. 
 
Spirometry for Identification of Airflow Obstruction and Restrictive Pattern 
Spirometry was performed by trained and certified nurses and technicians 12. Pre-
bronchodilator testing was conducted while sitting, except for participants with BMI >27 
kg/m2 who stood. Maneuvers were considered acceptable to then-current 1994 American 




Spirometric measurements FEV1, FVC, and FEV1/FVC were used in analyses. 
Reference values for SHS participants were derived previously 12 yielding FVC 
%predicted and FEV1 %predicted. The prevalence of airflow obstruction was defined by 
a fixed ratio of FEV1/FVC<0.70 using crude values 14. A low FVC (<80 %predicted) 
together with a preserved ratio (FEV1/FVC≥0.70) was defined as restrictive pattern 15. 
Healthy individuals (controls) were those with no-obstruction and no-restriction 
(FEV1/FVC>0.70 and FVC>80 %predicted). We conducted secondary analyses with the 
lower limit of normal (LLN = 5th percentile of the frequency distribution of reference 
values; obstruction: FEV1/FVC <LLN; restriction: FEV1/FVC >LLN and FVC <LLN; 
healthy: FEV1/FVC >LLN and FVC >LLN). 
 
Symptoms and Lung Disease 
At Visit 2, participants were asked to report respiratory symptoms including 
cough (“Do you usually have a cough?”, frequent cough (“Do you usually cough as much 
as 4-6 times/day, 4 or more days/week?”), cough with phlegm (“Do you usually bring up 
phlegm when you cough?”), shortness of breath (“Are you troubled by shortness of 
breath when hurrying on the level or walking up a slight hill?”), and stopping for breath 
while walking (“Do you ever have to stop for breath while walking about 100 yards or a 
few minutes on the level?”). Participants self-reported emphysema, asthma, or chronic 





At the baseline visit, sociodemographic (age, sex, education, and study site) and 
life-style (smoking status and smoking pack-years) variables were ascertained through a 
standardized questionnaire by trained and certified interviewers 8. Smoking status was 
categorized as never, former, or current. Former: smoked 100 cigarettes but no longer 
smoking; Never: smoked <100 cigarettes in lifetime; and Current: smoking at then-
present day. Height and weight measurements for BMI calculation (weight in kilograms 
divided by height in meters squared) were conducted during the physical exam. Chronic 
kidney disease was defined as estimated glomerular filtration rate (eGFR) < 60 
ml/min/1.73m2 based on serum creatinine using the Modification of Diet in Renal Disease 
equation 16. Diabetes was defined as a fasting glucose level of 126 mg/dL, a 2-hour 
post-load plasma glucose level of 200 mg/dL, an HbA1c level of 6.5%, or use of an 
oral hypoglycemic agent or insulin 17.  
At Visit 2, a medical record review for a history of active and treated tuberculosis 
(class III tuberculosis) was performed. Case definition for class III tuberculosis involved 
having a positive culture for Myco bacterium tuberculosis from a body fluid or tissue or 
having a clinical picture suggestive of tuberculosis that responded to treatment with 
antitubercular medications. If the individual had active tuberculosis listed on a discharge 
diagnosis or on a problem list, they were considered to have a history of tuberculosis.  
Statistical analysis 
We conducted descriptive statistics to evaluate differences in participant 
demographic and lifestyle variables by obstruction and restrictive pattern and by urinary 
arsenic tertile. We used logistic regression to estimate the odds ratio [OR] for presence of 
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obstruction/restrictive pattern, respiratory symptoms and disease by urinary arsenic 
concentrations, and linear regression to assess the mean difference of spirometric 
measurements. We modelled arsenic exposure using three approaches: a categorical 
variable, comparing tertiles of arsenic exposure; a continuous variable to compare an 
interquartile (IQR) increase of log urinary arsenic; and a continuous variable with splines 
with knots at the 10th, 50th, and 90th percentiles (3.8, 10.2, and 25.8 µg/g creatinine, 
respectively) to allow for a flexible dose-response relationship. P values for trend were 
obtained from modelling log-arsenic as continuous. Models were progressively adjusted 
(see footnotes of Tables 3, 4, 6).  
Effect modification of the association was evaluated depending on confounding 
variables by including interaction terms for log-transformed urinary arsenic 
concentrations with indicator variables for sex, age, smoking status, BMI, and diabetes. P 
values for interactions were obtained using Wald test for multiple coefficients. To 
evaluate arsenic metabolism, we examined the association between the relative 
proportions of arsenic species in urine per 5% change and presence of 
obstruction/restrictive pattern.  
 
RESULTS 
Obstruction was present in 21.5% (458/2,132) and restrictive pattern present in 
14.4% (307/2,132). Obstruction and restrictive pattern demographics are described in 
Table 1. Obstruction was present in 31.0% vs. 20.7% of participants in the highest vs. 
lowest arsenic exposure tertiles (p=0.02); restrictive pattern was present in 23.8% vs. 




After full adjustment (Table 3, model 3), the odds ratio [95% CI] comparing the highest 
to lowest arsenic tertile (≥14.0 vs. ≤7.0 µg/g creatinine) was 1.33 [0.99, 1.77] for 
obstruction and 1.34 [0.92, 1.96] for restrictive pattern. The corresponding OR [95%CI] 
comparing an interquartile range (IQR) of arsenic was 1.17 [0.99, 1.38] (P for trend 0.07) 
for obstruction and 1.27 [1.01, 1.60] (P for trend 0.04) for restrictive pattern (Table 3, 
model 3). Modelling urinary arsenic using flexible splines, there was some departure 
from linearity (Figure 1). Results were unchanged in analyses excluding 5 participants 
above the 99th percentile of %predicted FEV1 and FVC (results not shown). In a 
sensitivity analysis with further adjustment for diabetes, the OR for obstruction per 
change in arsenic IQR remained similar (1.17 [0.99, 1.40] (P for trend 0.07)), and for 
restrictive pattern the OR was attenuated (1.18 [0.93, 1.50] (P for trend 0.18)) (Table 3).  
Using the LLN definition, obstruction was present in 7.1% (151/2,132) and 
restrictive pattern in 6.9% (147/2,132). The ORs for the association based on the LLN 
were stronger compared to the fixed ratio and were significant for obstruction (OR 
[95%CI] per IQR) (1.28 [1.02, 1.60] (P for trend 0.03) but non-significant for restriction 
(1.33 [0.90, 1.50] (P for trend 0.06) (Table 4).  
The mean difference [95% CI] for FEV1 %predicted for an IQR change in urinary 
arsenic was -1.39 [-2.51, -0.25] (P for trend 0.02), although the trend was non-linear by 
tertile (Table 5) and flexible splines (Figure 2). The %predicted association remained 
significant after further adjustment for diabetes in the sensitivity analyses (Table 1S). For 
FVC %predicted, the mean difference [95% CI] per IQR change in arsenic was -1.13 [-
2.21, -0.05] (P for trend 0.04). Among the healthy group, the mean difference for FEV1 
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%predicted and FVC %predicted both became non-significant (Table 5) and remained 
non-significant in the sensitivity analysis (Table 1S). No association was found between 
arsenic and FEV1/FVC. Using crude FEV1 and FVC measures (mL) the mean 
differences were significant (Table 5).  
We found no effect modification for the association of arsenic with 
obstruction/restrictive pattern by age, BMI, or diabetes (Table 2S). By sex, effect 
modification was significant for obstruction (P= 0.003), with an association found in men 
(OR [95%CI]) (1.47 [1.07, 2.06]) but not significant in women (1.07 [0.82, 1.33]). By 
smoking status, the association with arsenic was strongest in former smokers both for 
obstruction (1.74 [1.20, 2.55]) and restrictive pattern (1.34 [0.82, 2.17]) compared to 
never or current smokers, but confidence intervals overlapped in both analyses. Urinary 
relative proportions of iAs, MMA, and DMA were not associated with 
obstruction/restrictive pattern (Table 4S). 
Urinary arsenic was inversely associated with cough (OR [95%CI] per IQR) (0.78 
[0.65, 0.93]), but not with frequent cough (4-6x/day) or production of phlegm (Table 6). 
There was no association between arsenic and shortness of breath, but arsenic was 
positively associated with stopping for breath while walking (1.41 [1.19, 1.69]) (Table 6). 
Urinary arsenic was positively associated with emphysema (OR [95%CI] per IQR) (1.66 
[1.29, 2.15]); inversely associated with  asthma (0.76 [0.61, 0.96]) and not associated 





Exposure to low-moderate levels of inorganic arsenic was associated with 
increased odds of fixed ratio restrictive lung pattern, lower FEV1 and lower FVC, 
borderline associated with fixed ratio obstruction, and not associated with FEV1/FVC. 
The associations based on the LLN became stronger and significant for obstruction and 
stronger but non-significant for restrictive pattern. Arsenic was also associated with 
stopping for breath while walking and with higher self-reported emphysema. The 
association with restrictive pattern is consistent with recent meta-analysis findings that 
suggested low-level arsenic exposure is a restrictive lung disease risk factor 4. There is 
debate over using the fixed ratio definition of obstruction, which can potentially lead to 
over-diagnoses in older patients 18, 19. However, there are also limitations with LLN-
defined obstruction, which can underestimate COPD 20. The stronger but non-significant 
effect estimates we observed for the association between arsenic and LLN-defined 
restrictive pattern may be due to a more specific definition and exclusion of less severe 
cases. 
Restrictive pattern findings remained significant after adjustment for smoking 
(status and pack-years), a major risk factor for reduced pulmonary function 21, 22. In a 
sensitivity analysis (results not shown), we adjusted for additional adiposity factors (% 
body fat, waist circumference) to account for mechanical constraints of obesity-related 
lung restriction 23 with consistent findings. Adjustment for diabetes, however, attenuated 
the association, which became non-significant. The definitive direction as well as the 
exact pathophysiological mechanism to explain the association between diabetes and lung 
function is not known 24; in the Strong Heart Study, impaired lung function presented 
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before the development of diabetes 25. Previous similar studies have not adjusted for 
diabetes, but a large body of evidence suggests that chronic arsenic exposure can 
contribute to diabetes development 26, and diabetes could be in the causal pathway 
between arsenic and restrictive lung pattern. 
There is consistent evidence that increasing arsenic exposure is associated with 
reports of coughing and breathing problems 5. However, we only found a positive 
association between arsenic and the need to stop for breath and a reduced odds of cough. 
One study in the US also found lower odds of chronic cough in participants with greater 
than the 80th arsenic percentile (<17.23 µg/L) compared to those with less than the 20th 
percentile (<3.52 µg/L) 6. The same study reported greater odds of self-reported 
emphysema, similar to our findings, among those with the highest quartile of urinary 
arsenic compared to the lowest, but results were non-significant 6. Four studies have 
examined arsenic and chronic bronchitis; three found a greater odds 27-29 and one found 
reduced odds.6  
Despite epidemiologic evidence, little is known regarding arsenic-induced effects 
on airway physiology 30, 31. Rather than a direct toxic effect of arsenic on the lung, an 
inflammation-mediated immunologic basis has been suggested 32, as arsenic is known to 
alter key functions of the innate and adaptive immune system 33-36. One possible 
mechanism is aberrant airway remodeling targeted by arsenic following activation of 
inflammatory mediators. Airway remodeling has been linked to the equilibrium between 
proteases matrix metalloproteinase-9 (MMP-9) and its inhibitors, receptor for advanced 
glycation end products (RAGE) 37. Loss of the soluble form of RAGE, sRAGE, is related 
to functional changes of pulmonary cell types, with consequences of fibrotic disease. 
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Arsenic may change RAGE gene expression by altering the promoter region methylation 
or by affecting transcriptional regulators of RAGE. In humans, sputum sRAGE levels 
were negatively correlated with urinary arsenic levels, similar to animal models 38. In 
vitro models have shown arsenic exposure increased activity and expression of MMP-9 in 
airway epithelial cells 39. 
This study had several limitations. We measured urinary arsenic levels in a single 
sample at baseline, while spirometric measurements were taken at Visit 2. However, the 
temporal stability of arsenic levels in drinking water and urine has been shown in this 
population 11. Spirometry was originally performed for better prediction of cardiovascular 
disease 13. We did not have total lung capacity measurements, often not available for 
large population screenings, and could not confirm restriction presence by methods other 
than spirometry. Thus, we cannot discard the possibility that the association we found 
may be due to mixed ventilatory defect. Outcome misclassification could have occurred 
from inaccurate recall of disease diagnosis. The reason we saw a significant relationship 
between arsenic and obstruction only in former smokers is unknown. A few studies have 
reported similar findings, with authors suggesting the toxic effects of smoking could be 
masking those of arsenic 27, 40.   
Strengths of this study include having American Indian reference values derived 
from the SHS cohort 12. This is important as anthropomorphic differences vary between 
ethnic groups, and NHANES III, from which normative values are generated, did not 
include American Indians. The reference values allowed for results to be evaluated for 
abnormalities against predicted values for better interpretation of results. Other major 
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strengths include the community-based sample, standardized spirometry, and extensive 
data on potential confounders. 
 
CONCLUSIONS 
Our study provides evidence of an association between low-moderate arsenic 
exposure and a spirometric restrictive pattern, airflow obstruction (especially based on 
the LLN), select respiratory symptoms, and higher self-reported emphysema. No other 
study has evaluated the association between arsenic exposure and individual spirometric 
lung function in American Indians, US population, or population exposed to low-
moderate arsenic levels. Research in additional populations is needed to confirm the 
association, including evaluation of relevant subclinical and pathophysiological 
outcomes. This could include repeated urinary arsenic measurement and diagnostic 














Table 1. Baseline (1998-1991) Participant Characteristics by Airflow Obstruction 












FEV1/FVC >0.70  




FEV1/FVC >0.70  




59.2 (0.3) 56.1 (0.5) 54.5 (0.2) 
Female 
 
226 (49.3%) 206 (67.1%) 860 (62.9%) 
Education    
  No high school (HS) 122 (26.6%) 68 (21.1%) 187 (13.7%) 
  Some HS 111 (24.2%) 69 (22.4%) 313 (22.9%) 
  Completed HS or higher 
 
225 (49.2%) 170 (55.4%) 867 (63.4%) 
Smoking status    
  Never 113 (24.7%) 109 (35.5%) 451 (33.0%) 
  Former 134 (29.3%) 91 (29.6%) 443 (32.4%) 
  Current 
 
211 (46.1%) 107 (34.9%) 473 (34.6%) 
Smoking pack years 
 
18.2 (0.9) 9.2 (0.7) 8.2 (0.3) 
BMI, kg/m2 
 
29.0 (0.2) 33.0 (0.4) 31.4 (0.2) 
Diabetes 
 
168 (36.7%) 185 (60.3%) 539 (39.4%) 
Urine ∑As, µg/g creatinine 11.1 (6.2 - 16.1) 12.0 (6.2-20.2) 9.5 (5.6-15.7) 
iAs, % 8.5 (5.9 - 11.7) 7.6 (5.6-10.7) 7.7 (5.5-11.0) 
MMA, % 14.7 (11.3-18.5) 12.8 (10.5-16.2) 13.8 (10.8-17.2) 
    
FEV1, %predicted 77.7 (0.8) 73.6 (0.6) 100.2 (0.3) 
FVC, %predicted 93.9 (0.8) 69.4 (0.5) 98.6 (0.3) 
FEV1/FVC, % 62.2 (0.3) 81.4 (0.4) 78.2 (0.1) 
    
Inhaled steroids 8 (1.7%) 8 (2.6%) 36 (2.6%) 
    
Self-reported chronic bronchitis 59 (13.0%) 49 (16.1%) 112 (8.3%) 
Self-reported emphysema 34 (7.5%) 19 (6.3%) 25 (1.8%) 
Self-reported asthma 59 (13.1%) 40 (13.1%) 87 (6.4%) 
Medical record tuberculosis 83 (18.1%) 54 (17.6%) 155 (11.3%) 
    
Self-reported cough 140 (30.6%) 84 (27.5%) 252 (18.5%) 
Cough 4-6x/week 92 (64.8%) 54 (63.5%) 158 (61.5%) 
Phlegm 89 (62.2%) 51 (60.0%) 161 (59.9%) 
Shortness of breath 221 (48.6%) 169 (57.1%) 585 (43.1%) 
Stopping for breath 97 (41.8%) 72 (42.4%) 186 (31.3%) 
All analyses are weighted. Data are mean (SE), n (% of column), or median (interquartile range) 





Table 2. Participant Characteristics by Baseline (1998-1991) Urinary Arsenic 
Concentration* (N=2,132) 
     















55.6 55.6 56.0 0.37 
Female 
 
494 (56.0%) 443 (61.1%) 355 (67.6%) <0.001 
Education    <0.001 
  No high school (HS) 80 (9.1%) 149 (20.6%) 148 (28.2%)  
  Some HS 202 (22.9%) 160 (22.1%) 131 (25.0%)  
  Completed HS or higher 
 
600 (68.0%) 416 (57.4%) 246 (46.9%)  
BMI, kg/m2 
 
30.8 (0.1) 31.3 (0.2) 31.6 (0.3) 0.01 
Diabetes 
 
317 (35.9%) 296 (40.8%) 279 (53.1%) <0.001 
Smoking status    0.06 
  Never 292 (33.9%) 214 (29.5%) 167 (31.8%)  
  Former 288 (32.6%) 235 (32.4%) 145 (27.6%)  
  Current 
 
302 (34.2%) 276 (38.1%) 213 (40.5%)  
Smoking pack years 
 
11.4 (0.4) 10.8 (0.4) 8.9 (0.5) <0.001 
FEV1, %predicted 92.8 (0.4) 92.5 (0.6) 88.7 (0.7) <0.001 
FVC, %predicted 93.3 (0.4) 95.0 (0.6) 90.3 (0.7) <0.001 
FEV1/FVC, % 76.1 (0.2) 74.9 (0.3) 75.6 (0.4) 0.21 
     
Airflow obstruction◊ 157 (20.7%) 167 (26.3%) 134 (31.0%) 0.02 
Restrictive pattern‡ 125 (17.2%) 89 (15.9%) 93 (23.8%) <0.001 
     
Self-reported chronic 
bronchitis 
82 (9.2%) 78 (10.8%) 60 (11.4%) 0.59 
Self-reported emphysema 33 (3.7%) 26 (3.6%) 19 (3.6%) 0.43 
Self-reported asthma 77 (8.8%) 65 (9.0%) 44 (8.4%) 0.51 
Medical record 
tuberculosis 
133 (15.1%) 99 (13.7%) 60 (11.4%) 0.02 
All analyses are weighted. Data are mean (SE) or n (% of tertile) 
*Tertiles are range; calculated based on overall population; sum of inorganic and methylated species µg/g creatinine 
**For continuous variables, ANOVA was used to calculate p-value; for categorical variables, chi-square test was 
used 
◊ Fixed airflow obstruction: FEV1/FVC <0.70 




Table 3. Weighted Odds Ratio (95% Confidence Interval) of Airflow Obstruction 
and Restrictive Pattern, Defined Based on Fixed Ratios, by Urinary Arsenic 
Concentration*   
 


















157/600 167/469 134/298 458/1367  
  Model 1 1.00 (Ref) 1.15 (0.93, 1.43) 1.45 (1.10, 1.91) 1.27 (1.08, 1.51) 0.005 
  Model 2 1.00 (Ref) 1.11 (0.89, 1.39) 1.34 (1.01, 1.77) 1.21 (1.01, 1.43) 0.03 
  Model 3 1.00 (Ref) 1.12 (0.90, 1.40) 1.33 (0.99, 1.77) 1.17 (0.99, 1.38) 0.07 
  Model 4 1.00 (Ref) 1.12 (0.90, 1.41) 1.33 (0.99, 1.79) 1.17 (0.99, 1.40) 0.07 
      
Restrictive patternα/ 
HealthyΩ 
125/600 89/469 93/298 307/1367  
  Model 1 1.00 (Ref) 0.92 (0.69, 1.23) 1.32 (0.92, 1.91) 1.25 (0.99, 1.57) 0.06 
  Model 2 1.00 (Ref) 0.91 (0.68, 1.22) 1.30 (0.90, 1.89) 1.23 (0.98, 1.55) 0.07 
  Model 3 1.00 (Ref) 0.92 (0.68, 1.23) 1.34 (0.92, 1.96) 1.27 (1.01, 1.60) 0.04 
  Model 4 1.00 (Ref) 0.88 (0.65, 1.19) 1.16 (0.78, 1.73) 1.18 (0.93, 1.50) 0.18 
† Fixed airflow obstruction: FEV1/FVC <0.70 
Ω Healthy: FEV1/FVC >0.70 & FVC >80% predicted 
α Restrictive pattern: FEV1/FVC >0.70 & FVC <80% predicted 
*Tertiles are range; calculated based on overall population; sum of iAs, MMA, DMA µg/g creatinine 
**P-trend calculated modeling log-arsenic as continuous 
‡ Comparison of the 75th and 25th percentiles (interquartile range) of urinary arsenic concentrations (16.7 vs. 5.8 µg/g 
creatinine) 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for eGFR, tuberculosis, and BMI 






























Table 4. Weighted Odds Ratio (95% Confidence Interval) of Airflow Obstruction 
and Restrictive Pattern, Defined Based on the Lower Limit of Normal (LLN), by 
Urinary Arsenic Concentration* (N= 2132)  
 

















47/773 57/626 47/435 151/1,834  
  Model 1 1.00 (Ref) 1.15 (0.84, 1.58) 1.64 (1.16, 2.34) 1.47 (1.17, 1.88) 0.001 
  Model 2 1.00 (Ref) 1.11 (0.80, 1.53) 1.50 (1.05, 2.15) 1.38 (1.09, 1.76) 0.007 
  Model 3 1.00 (Ref) 1.08 (0.78, 1.50) 1.36 (0.94, 1.97) 1.28 (1.02, 1.60) 0.03 
  Model 4 1.00 (Ref) 1.07 (0.78, 1.49) 1.33 (0.92, 1.93) 1.26 (1.01, 1.59) 0.04 
      
Restrictive patternα/ 
Healthy Ω 
62/773 42/626 43/435 147/1,834  
  Model 1 1.00 (Ref) 0.85 (0.58, 1.26) 1.45 (0.91, 2.30) 1.33 (1.00, 1.76) 0.05 
  Model 2 1.00 (Ref) 0.85 (0.58, 1.26) 1.41 (0.88, 2.25) 1.30 (0.98, 1.74) 0.07 
  Model 3 1.00 (Ref) 0.86 (0.58, 1.28) 1.42 (0.88, 2.28) 1.33 (0.90, 1.50) 0.06 
  Model 4 1.00 (Ref) 0.83 (0.56, 1.23) 1.23 (0.76, 2.00) 1.21 (0.90, 1.64) 0.22 
† Airflow obstruction: FEV1/FVC <LLN 
α Restrictive pattern: FEV1/FVC >LLN & FVC <LLN 
Ω Healthy: FEV1/FVC >LLN and FVC >LLN 
*Tertiles are range; calculated based on overall population; sum of iAs, MMA, DMA µg/g creatinine 
**P-trend calculated modeling log-arsenic as continuous 
‡ Comparison of the 75th and 25th percentiles (interquartile range) of urinary arsenic concentrations (16.7 vs. 5.8 µg/g 
creatinine) 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for eGFR, tuberculosis, and BMI 





























Table 5. Weighted Mean Difference (95% Confidence Interval) of Lung Function at 
Visit 2 (1993-1995) by Urinary Arsenic Concentration* at Baseline (1989-1991) 
 













75th vs. 25th Percentile‡  
FEV1, % 
predicted 
      
All 2132 0 (Ref) 0.92 (-0.52, 2.37) -1.64 (-3.60, 0.32) -1.39 (-2.51, -0.25) 0.02 
  Healthy α 1367 0 (Ref) 0.67 (-0.86, 2.19) -0.49 (-2.58, 1.61) 0.85 (0.27, 2.74) 0.80 
       
FVC, % 
predicted 
      
All 2132 0 (Ref) 2.09 (0.72, 3.47) -1.01 (-2.85, 0.83) -1.13 (-2.21, -0.05) 0.04 
  Healthy α 1367 0 (Ref) 1.15 (-0.23, 2.53) -0.73 (-2.60, 1.14) 0.70 (0.24, 2.02) 0.50 
       
FEV1/FVC (%)       
All 2132 0 (Ref) -0.62 (-1.26, 0.002) -0.16 (-1.01, 0.69) 0.09 (-0.46, 0.66) 0.74 
  Healthy α 1367 0 (Ref) -0.31 (-0.85, 0.25) 0.26 (-0.49, 1.01) 1.21 (0.76, 1.94) 0.42 
       
FEV1, mL       
All 2132 0 (Ref) 0.007 (-0.04, 0.06) -0.09 (-0.15, -0.03) -0.07 (-0.11, -0.03) <0.001 
  Healthy α   1367 0 (Ref) 0.003 (-0.05, 0.06) -0.06 (-0.14, 0.01) -0.03 (-0.07, -0.003) 0.07 
       
FVC, mL       
All 2132 0 (Ref) 0.06 (-0.004, 0.11) -0.10 (-0.17, -0.02) -0.07 (-0.12, -0.03) 0.001 
  Healthy α   1367 0 (Ref) 0.02 (-0.05, 0.09) -0.09 (-0.19, -0.0001) -0.05 (-0.10, -0.004) 0.03 
α Healthy: FEV1/FVC >0.70 & FVC >80% predicted 
 Adjusted for age, sex, education, site, smoking status, smoking pack-year, eGFR, tuberculosis, and BMI 
 
*Tertiles are range; calculated based on overall population; sum of inorganic and methylated species µg/g 
creatinine 
‡ Comparison of the 75th and 25th percentiles (interquartile range) of the sum inorganic and methylated 
urinary arsenic concentrations (16.7 vs. 5.8 µg/g creatinine) 















Table 6. Weighted Odds Ratio (95% Confidence Interval) of Respiratory Symptom 
by Urinary Arsenic Concentration (N=2,132) 
 











75th vs. 25th 
Percentile 
 
Cough**/No cough  191/690 169/555 116/406 476/1651  
  Model 1 1.00 (Ref) 0.87 (0.70, 1.09) 0.69 (0.51, 0.93) 0.82 (0.69, 0.98) 0.03 
  Model 2 1.00 (Ref) 0.86 (0.69, 1.06) 0.64 (0.48, 0.87) 0.79 (0.66, 0.93) 0.006 
  Model 3 1.00 (Ref) 0.84 (0.68, 1.05) 0.63 (0.47, 0.86) 0.78 (0.65, 0.93) 0.005 
  Model 4 1.00 (Ref) 0.84 (0.68, 1.05) 0.63 (0.46, 0.85) 0.77 (0.65, 0.92) 0.004 
 










  Model 1 1.00 (Ref) 0.97 (0.73, 1.28) 0.86 (0.59, 1.26) 0.96 (0.78, 1.18) 0.71 
  Model 2 1.00 (Ref) 0.94 (0.71, 1.24) 0.79 (0.54, 1.16) 0.91 (0.73, 1.12) 0.36 
  Model 3 1.00 (Ref) 0.94 (0.71, 1.25) 0.80 (0.54, 1.17) 0.92 (0.74, 1.13) 0.44 
  Model 4 1.00 (Ref) 0.94 (0.71, 1.25) 0.81 (0.55, 1.18) 0.93 (0.75, 1.15) 0.48 
      
Phlegm†/No  117/765 114/611 70/455 301/1831  
Model 1 1.00 (Ref) 1.19 (0.95, 1.49) 1.06 (0.77, 1.47) 1.09 (0.90, 1.31) 0.37 
Model 2 1.00 (Ref) 1.16 (0.93, 1.46) 0.99 (0.71, 1.37) 1.03 (0.86, 1.25) 0.71 
Model 3 1.00 (Ref) 1.18 (0.94, 1.49) 1.01 (0.73, 1.41) 1.05 (0.87, 1.27) 0.57 
Model 4 1.00 (Ref) 1.18 (0.94, 1.48) 1.01 (0.72, 1.40) 1.05 (0.87, 1.27) 0.59 
      
Shortness of breath‡/No  369/503 363/355 243/275 975/1133  
  Model 1 1.00 (Ref) 1.16 (0.98, 1.37) 0.90 (0.72, 1.13) 1.02 (0.88, 1.17) 0.81 
  Model 2 1.00 (Ref) 1.16 (0.98, 1.37) 0.88 (0.70, 1.11) 1.00 (0.87, 1.15) 0.97 
  Model 3 1.00 (Ref) 1.17 (0.98, 1.39) 0.93 (0.73, 1.18) 1.08 (0.93, 1.23) 0.34 
  Model 4 1.00 (Ref) 1.18 (0.99, 1.40) 0.94 (0.74, 1.20) 1.08 (0.94, 1.25) 0.28 
 










  Model 1 1.00 (Ref) 1.67 (1.35, 2.07) 1.56 (1.18, 2.06) 1.33 (1.11, 1.59) 0.002 
  Model 2 1.00 (Ref) 1.66 (1.34, 2.05) 1.52 (1.14, 2.01) 1.30 (1.08, 1.55) 0.005 
  Model 3 1.00 (Ref) 1.76 (1.42, 2.19) 1.68 (1.26, 2.24) 1.41 (1.19, 1.69) <0.001 
  Model 4 1.00 (Ref) 1.76 (1.41, 2.19) 1.64 (1.23, 2.20) 1.40 (1.17, 1.67) <0.001 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for eGFR, tuberculosis, and BMI 
Model 4: sensitivity analysis: further adjusted for diabetes 
*Tertiles are range; calculated based on overall population; sum of inorganic and methylated species µg/g creatinine 
ΩP-trend calculated modeling log-arsenic as continuous 
**Do you usually have a cough? 
∆Do you usually cough as much as 4-6 times/day, 4 or more days/week? 
†Do you usually bring up phlegm when you cough? 
‡Are you troubled by shortness of breath when hurrying on the level or walking up a slight hill? 












Figure 1. Dose-Response Relationship of Fixed Airflow Obstruction and Restrictive 
Patterns with Urinary Arsenic Concentrations. Solid lines and shaded areas 
surrounding the lines represent the weighted odds ratio and 95% confidence intervals of 
airflow obstruction (upper panels) and restrictive pattern (lower panels). Models were 
conducted in the total study sample (left panels), stratified by sex (middle panels), and 
stratified by smoking status (right panels). These models were adjusted for age, sex 
(except models stratified by sex), education, study site, smoking status (except models 
stratified by smoking status), smoking pack-year, eGFR, tuberculosis and BMI. 
Histograms in the background and right Y axis represent the distribution of urinary 
arsenic. The histograms were truncated by excluding 10 participants with urine arsenic 















Figure 2. Dose-Response Relationship of Lung Function at Visit 2 (1993 – 1995) with 
Urinary Arsenic Concentrations. Solid lines and shaded areas surrounding the lines 
represent the weighted mean differences and 95% confidence intervals of FEV1 % 
predicted (right panels), FVC % predicted (middle panels), and FEV1/FVC (right panels). 
Models were conducted in the total study sample (upper panels) and stratified by sex 
(lower panels). These models were adjusted for age, sex (except models stratified by sex), 
education, study site, smoking status, smoking pack-year, eGFR, tuberculosis and BMI. 
Histograms in the background and right Y axis represent the distribution of urinary 
arsenic. The histograms were truncated by excluding 10 participants with urine arsenic 





















Supplement table 1S. Sensitivity Analysis: adjustment for diabetes. Weighted Mean 
Difference (95% Confidence Interval) of Lung Function at Visit 2 (1993-1995) by 
Urinary Arsenic Concentration* at Baseline (1989-1991) 
 

















      
All 2132 0 (Ref) 0.91 (-0.56, 2.39) -1.44 (-3.44, 0.56) -1.28 (-2.39, -0.17) 0.02 
  Healthy α 1367 0 (Ref) 0.67 (-0.86, 2.20) -0.47 (-2.60, 2.20) 0.87 (0.27, 2.80) 0.82 
       
FVC, % 
predicted 
      
All 2132 0 (Ref) 2.16 (0.77, 3.56) -0.54 (-2.41, 1.34) -0.85 (-1.91, 0.22) 0.12 
  Healthy α 1367 0 (Ref) 1.20 (-0.20, 2.59) -0.49 (-2.40, 1.43) 0.79 (0.27, 2.32) 0.67 
       
FEV1/FVC 
(%) 
      
All 2132 0 (Ref) -0.70 (-1.36, -0.05) -0.36 (-1.23, 0.52) -0.01 (-0.58, 0.55) 0.97 
  Healthy α 1367 0 (Ref) -0.35 (-0.89, 0.20) 0.08 (-0.66, 0.81) 1.10 (0.69, 1.74) 0.68 
α Healthy: FEV1/FVC >0.70 & FVC >80% predicted 
Adjusted for age, sex, education, site, smoking status, smoking pack-year, eGFR, tuberculosis, BMI, and diabetes 
 
*Tertiles are range; calculated based on overall population; sum of inorganic and methylated species µg/g creatinine 
‡ Comparison of the 75th and 25th percentiles (interquartile range) of the sum inorganic and methylated urinary arsenic 
concentrations (16.7 vs. 5.8 µg/g creatinine) 

























Supplemental table 2S. Weighted Odds Ratios (95% Confidence Interval) for 
Airflow Obstruction and Restrictive Pattern, Defined Based on Fixed Ratios, when 
an Interquartile Range* of Urinary Arsenic Concentration is Compared, by 
Participant Characteristics at Baseline 
*Interquartile range of the sum inorganic and methylated urinary arsenic concentrations was 5.8 to 16.7 µg/g creatinine 
α Compared to Healthy: FEV1/FVC >0.70 & FVC >80% predicted 
**ORs were stratified by each subgroup of interest, and associated P values for interaction were obtained from models 
with interaction terms and using Wald tests for multiple coefficients 
Models were adjusted for sex, age, education, site, smoking status, cigarette pack-years, body mass index, estimated 
glomerular filtration rate, and tuberculosis.  



















 Airflow obstruction α Restrictive pattern α 
 FEV1/FVC <0.70 FEV1/FVC >0.70 & FVC <80% predicted 
Variable N Odds 
Ratio 




95% CI P for 
interaction** 
Sex    0.003    0.82 
  Male 739 1.47 (1.07, 2.06)  608 1.10 (0.69, 1.76)  
  Female 1086 1.07 (0.82, 1.33)  1066 1.23 (0.90, 1.69)  
         
Age‡, years    0.52    0.43 
  <55.7 977 1.31 (1.01, 1.71)  965 1.30 (0.91, 1.86)  
  ≥55.7  848 1.12 (0.85, 1.47)  709 1.06 (0.74, 1.54)  
         
Smoking status    0.12    0.03 
  Never 564 0.88 (0.57, 1.37)  560 0.99 (0.60, 1.64)  
  Former 577 1.74 (1.20, 2.55)  534 1.34 (0.82, 2.17)  
  Current 684 1.10 (0.81, 1.51)  580 1.16 (0.79, 1.73)  
         
BMI, kg/m2    0.15    0.31 
  <25  317 1.51 (0.99, 2.29)  220 0.91 (0.39, 2.11)  
  ≥25 - <30 646 1.29 (0.93, 1.78)  578 1.67 (1.09, 2.57)  
  ≥30 862 0.89 (0.62, 1.29)  876 1.04 (0.72, 1.51)  
         
Diabetes    0.84    0.60 
  Yes 707 1.05 (0.71, 1.57)  724 1.17 (0.82, 1.69)  
  No 1,118 1.23 (0.99, 1.54)  950 1.08 (0.74, 1.59)  
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Supplemental table 3S. Weighted Odds Ratio (95% Confidence Interval) of Self-
reported Emphysema, Chronic Bronchitis, or Asthma by Urine Arsenic Tertile 
Concentration  
 
 Inorganic Plus Methylated Arsenic Species µg/g 
creatinine 
 















82/797 78/638 60/461 220/1896  
  Model 1 1.00 (Ref) 1.15 (0.85, 1.56) 1.19 (0.79, 1.81) 1.13 (0.90, 1.44) 0.29 
  Model 2 1.00 (Ref) 1.14 (0.84, 1.54) 1.16 (0.76, 1.75) 1.11 (0.88, 1.40) 0.37 
  Model 3 1.00 (Ref) 1.14 (0.84, 1.56) 1.20 (0.79, 1.83) 1.16 (0.92, 1.47) 0.22 
  Model 4 1.00 (Ref) 1.14 (0.84, 1.55) 1.17 (0.76, 1.79) 1.15 (0.90, 1.46) 0.27 
      
Emphysema/None 
(N=2,116) 
33/847 26/692 19/499 78/2038  
  Model 1 1.00 (Ref) 1.23 (0.88, 1.74) 2.04 (1.35, 3.08) 1.76 (1.38, 2.27) <0.001 
  Model 2 1.00 (Ref) 1.18 (0.83, 1.67) 1.79 (1.16, 2.77) 1.64 (1.27, 2.09) <0.001 
  Model 3 1.00 (Ref) 1.18 (0.83, 1.67) 1.83 (1.18, 2.83) 1.66 (1.29, 2.15) <0.001 
  Model 4 1.00 (Ref) 1.17 (0.82, 1.66) 1.79 (1.16, 2.78) 1.66 (1.27, 2.13) <0.001 
      
Asthma/None 
(N=2,117) 
77/800 65/653 44/478 186/1931  
  Model 1 1.00 (Ref) 0.91 (0.67, 1.25) 0.61 (0.40, 0.94) 0.76 (0.60, 0.96) 0.02 
  Model 2 1.00 (Ref) 0.90 (0.66, 1.23) 0.60 (0.39, 0.93) 0.75 (0.60, 0.95) 0.02 
  Model 3 1.00 (Ref) 0.90 (0.66, 1.23) 0.61 (0.40, 0.95) 0.76 (0.60, 0.96) 0.02 
  Model 4 1.00 (Ref) 0.90 (0.66, 1.24) 0.63 (0.41, 0.97) 0.77 (0.61, 0.98) 0.03 
*Tertiles are range; calculated based on overall population; sum of inorganic and methylated species µg/g creatinine 
**P-trend calculated modeling log-arsenic as continuous 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for eGFR, tuberculosis, and BMI 

























Supplemental table 4S. Weighted Odds Ratio (95% Confidence Interval) of Airflow 
Obstruction and Restrictive Pattern, Defined Based on Fixed Ratios, by 5% Change 
in Urinary Arsenic Metabolites* 
 




   
Model 3 1.04 (0.93, 1.15) 0.92 (0.83, 1.02) 1.02 (0.96, 1.09) 
Model 4 1.04 (0.93, 1.15) 0.92 (0.83, 1.02) 1.04 (0.93, 1.15) 
    
Restrictive pattern/Healthy 
(280/1,282) 
   
Model 3 0.95 (0.81, 1.12) 0.88 (0.77, 1.00) 1.07 (0.98, 1.17) 
Model 4 0.94 (0.80, 1.11) 0.93 (0.81, 1.07) 1.05 (0.96, 1.14) 
 *sum of inorganic and methylated species µg/g creatinine 
Airflow obstruction: FEV1/FVC <0.70 
Healthy: FEV1/FVC >0.70 & FVC >80% predicted 
Restrictive pattern: FEV1/FVC >0.70 & FVC <80% predicted 
Model 3: adjusted for age, sex, education, site, smoking status, smoking pack-year, eGFR, tuberculosis, and BMI 
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Background: Permanent lung function impairment after active tuberculosis infection is 
relatively common. It remains unclear which spirometric pattern is most prevalent after 
tuberculosis. Our objective was to elucidate the impact of active tuberculosis survival on 
lung health in the Strong Heart Study, a population of American Indians historically 
highly impacted by tuberculosis. As arsenic exposure has also been related to lung 
function in the Strong Heart Study, we also assessed the joint effect between arsenic 
exposure and past active tuberculosis. 
Methods: The Strong Heart Study is an ongoing population-based, prospective study of 
cardiovascular disease and its risk factors in American Indian adults. This study uses 
tuberculosis data and spirometry data from the Visit 2 examination (1993-1995). Prior 
active tuberculosis was ascertained by a review of medical records. FVC, FEV1, and 
FEV1/FVC were measured by spirometry. An additional analysis was conducted to 
evaluate the potential association between active tuberculosis and arsenic exposure. 
Results: A history of active tuberculosis was associated with reduced percent predicted 
FVC and FEV1, an increased odds of airflow obstruction (odds ratio 1.45, 95% CI 1.08, 
1.95), and spirometric restrictive pattern (odds ratio 1.73, 95% CI 1.24, 2.40). These 
associations persisted after adjustment for diabetes and other risk factors, including 
smoking. We also observed the presence of cough, phlegm, and exertional dyspnea after 
a history of active tuberculosis. In the additional analysis, increasing urinary arsenic 
concentrations were associated with decreasing lung function in those with a history of 




Conclusions: Our findings support existing knowledge that a history of active 
tuberculosis is a risk factor for long-term respiratory impairment. Arsenic exposure, 
although inversely associated with prior active tuberculosis, was associated with a further 
decrease in lung function among those with a prior active tuberculosis history. The 
possible interaction between arsenic and tuberculosis, as well as the reduced odds of 
tuberculosis associated with arsenic exposure, warrants further investigation, as many 

















Tuberculosis, a preventable and treatable infectious disease when drug therapies 
are successful, largely affects vulnerable populations, including indigenous peoples, such 
as American Indians. Worldwide, indigenous populations are at a higher risk of 
tuberculosis than non-indigenous populations due to a higher than average prevalence of 
predisposing risk factors, including diabetes, smoking, and socioeconomic 
circumstances.1 Historically, tuberculosis was an important cause of mortality in 
American Indians, with peak disease likely around 1910.2 Even as mortality, morbidity, 
and risk of infection from tuberculosis have greatly decreased among American Indians, 
incidence rates remain above that of the non-foreign born non-Hispanic White 
population.1, 3 
A recent systematic review found that pulmonary impairment is relatively 
common among those with a history of tuberculosis.4 Even after microbiologic cure of 
the infectious disease, tuberculosis can be associated with long-term pulmonary damage, 
and this impairment, which can involve airflow obstruction and/or spirometric restrictive 
pattern defects,4 contributes to an unmeasured burden of chronic lung disease.5, 6   
In this study, we evaluated the relationship between a history of active 
tuberculosis and subsequent lung function in American Indians participating in the Strong 
Heart Study (SHS), a population-based study that represents Tribal Nations across four 
states in the United States (US). We assessed this association using data from a medical 
record-based history of active tuberculosis, spirometric measurements, and self-reported 
respiratory symptoms.  
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We also conducted an additional analysis to evaluate the potential association 
between tuberculosis and arsenic. In the US, elevated exposure to arsenic 
disproportionately affects populations relying on private well water. This includes many 
American Indian communities where naturally occurring arsenic is often above 10 µg/L, 
the current US Environmental Protection Agency (EPA) safety standard. In the SHS 
population, arsenic levels in drinking water were stable and relatively high before 2006, 
when new water systems were introduced in some of the communities to comply with the 
US EPA safety standard. For decades, participants were thus exposed to relatively high 
arsenic exposure levels.7 At present, one study found high arsenic exposure associated 
with higher tuberculosis mortality in Chile.8 In the SHS cohort, low-moderate arsenic 
exposure (<100 µg/L), which is widely prevalent in study communities,7 was positively 
associated with a spirometric restrictive pattern, airflow obstruction, and lower lung 
function, independent of active tuberculosis history (under review). There is also prior 
knowledge that arsenic is an immunosuppressant.9, 10 Given these previous findings, we 
examined whether a history of active tuberculosis was associated with arsenic exposure 
and possible interaction between arsenic and tuberculosis on lung disease.  
The SHS provides a unique opportunity to examine the lung health of participants 
who have been previously treated for active tuberculosis, allowing for the assessment of 
this burden compared to community members not affected by active tuberculosis, in a 
population-based study. We undertook this study to characterize the association of an 
active tuberculosis diagnosis on long-term functional pulmonary impairment in an 





The SHS is an ongoing, population-based, prospective study of cardiovascular 
disease and its risk factors in American Indian adults. The SHS recruited 4,549 residents 
of Tribal Nations located in Arizona (AZ), Oklahoma (OK), and North Dakota and South 
Dakota (ND/SD) in the US. Study enrollment rates of eligible participants were 71.8% in 
AZ, 61.5% in OK, and 55.3% in ND/SD.11 All men and women aged 45 to 74 years at the 
baseline visit in 1989-1991 were invited to participate. Compared with nonparticipants, 
participants were similar in age, body mass index, and diabetes status, and were more 
likely to be female.11 Participants were invited to subsequent clinical visits between 
1993-1995 and 1998-1999.12  
This study uses tuberculosis data and spirometry data from the Visit 2 
examination (1993-1995), available in 2,625 participants. We further excluded 123 
participants missing data on cigarette pack-years, 33 participants missing diabetes status, 
and 36 missing body mass index (BMI) and waist circumference, leaving 2,463 
individuals for this study. 
Data collection 
Visit 1 (1989-1991) and Visit 2 (1993-1995) included biospecimen collection, a 
physical exam, and an interviewer-administered standardized questionnaire. Visits were 





At Visit 2, a medical record review for a history of active and treated tuberculosis 
(class III tuberculosis) was performed. Case definition for class III tuberculosis involved 
having a positive culture for Mycobacterium tuberculosis from a body fluid or tissue or 
having a clinical picture suggestive of tuberculosis that responded to treatment with 
antitubercular medications. If any of those criteria were identified on a discharge 
diagnosis or on a problem list, they were considered to have a history of active 
tuberculosis. How the individual met the case definition, positive culture vs. response to 
treatment, was not available. If there was uncertainty about whether the lab results met 
the case definition, the medical record was reviewed by Dr. Tom Welty, co-author of this 
study. Dr. Welty, a retired physician from the US Indian Health Service and expert in 
clinical tuberculosis, developed the SHS data collection protocol and oversaw data 
collection and the identification of active tuberculosis based on available data in medical 
records at Visit 2. Participants received the diagnosis of active tuberculosis several years 
before the study visit (median (IQR) for the year of diagnosis was 1968 (1955-1979)). 
Tuberculosis status was specifically added to the SHS Visit 2 research protocol to 
establish prevalence of tuberculin positivity, refer study participants with positive 
tuberculin tests to Indian Health Service for appropriate evaluation and treatment, and 
establish a prevalence of history of active tuberculosis. A history of an active tuberculosis 
diagnosis was not differentiated between pulmonary or extra pulmonary. 
Spirometry for Identification of Airflow Obstruction and Restrictive Pattern 
Spirometry was performed by centrally trained and certified nurses and 
technicians at Visit 2.13 Pre-bronchodilator testing was conducted in the sitting position, 
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except for participants with BMI >27 kg/m2 who stood. Maneuvers were considered 
acceptable according to then-current American Thoracic Society recommendations; 
methods have been previously described.13, 14  
Spirometric measurements of forced vital capacity (FVC), forced expiratory 
volume in one second (FEV1), and their ratio (FEV1/FVC) were used in analyses. 
Reference values to determine the normal range of spirometry results for SHS 
participants were derived previously,13 yielding FVC % predicted and FEV1 % predicted. 
Airflow obstruction was defined two ways: 1) by a fixed ratio (FEV1/FVC<0.70) using 
crude FEV1 and FVC values,15 and 2) by the LLN (lower limit of normal), (FEV1/FVC 
<LLN), which classifies the bottom 5% of the ‘healthy’ population as abnormal (for the 
SHS, negative predictors of FEV1 were used to exclude participants from the healthy 
subset).13 Spirometric based restrictive pattern was defined two ways: 1) as a low FVC 
(FVC<80 % predicted) together with a preserved ratio (FEV1/FVC≥0.70),16 and 2) as the 
LLN (FEV1/FVC ≥LLN and FVC <LLN). Normal spirometry was defined as those with 
no-obstruction and no-restriction (fixed-ratio defined: FEV1/FVC≥0.70 and FVC>80 % 
predicted; LLN-defined: FEV1/FVC ≥LLN and FVC >LLN). 
Symptoms and Lung Disease 
At Visit 2, participants were asked to report respiratory symptoms, including the 
presence of cough, frequent cough, cough with phlegm, shortness of breath when walking 





Morning spot urine samples collected during the baseline visit were used to 
measure arsenic species (inorganic arsenic (iAs), methylarsonate (MMA), and 
dimethylarsinate (DMA)) using high performance liquid chromatography/inductively 
coupled plasma-mass spectrometry.12 Quality control and quality assurance methods and 
laboratory procedures for urine arsenic analysis were conducted in 2009-2010 using 
highly precise laboratory methods that are still state-of-the-art today.17 We used the sum 
of inorganic and methylated arsenic species (iAs+MMA+DMA) as the biomarker of 
exposure to inorganic arsenic in drinking water and food. Arsenobetaine levels were low, 
confirming that seafood intake is rare in the population. Urine creatinine was measured 
by an automated alkaline picrate methodology run on a rapid flow analyzer. To account 
for urine dilution in spot urine samples, urine arsenic (µg/L) was divided by urine 
creatinine concentrations (g/L) and the concentrations of total urine arsenic and its 
species were expressed in µg/g creatinine. 
 
Other variables 
Models were progressively adjusted for relevant lung health variables to correct 
for potential confounding, using data from Visit 2. In model 1, we adjusted for age, sex, 
education, and study site, potential demographic confounders. In our study population, 
arsenic levels in drinking water are higher in AZ, lower in OK, and intermediate in ND 
and SD, yet levels still overlap across sites, allowing us to adjust for site. Education is 
associated with arsenic exposure in our study, mostly related to the fact that those in AZ 
have on average a lower education level. In model 2, we adjusted for smoking status and 
cigarette pack-year, a well-established risk factor for lung disease, with smoking status 
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categorized as never, former (smoked 100 cigarettes but no longer smoking), or current 
(smoking at then-present day). In model 3, we adjusted for body mass index, waist 
circumference and percent body fat to account for adiposity impact on respiratory system 
compliance.18, 19 In model 4, we adjusted for diabetes, a highly prevalent risk factor found 
in the SHS cohort. Diabetes was defined as a fasting glucose level of 126 mg/dL, a 2-
hour post-load plasma glucose level of 200 mg/dL, an HbA1c level of 6.5%, or use of 
an oral hypoglycemic agent or insulin.20 To minimize any missing data, if Visit 2 data 
was missing for an individual, then baseline measurement was used (waist circumference: 
n= 5; body fat: n= 34; cigarette pack-years: n= 279; smoking status: n= 63).  
 
Statistical analysis 
We conducted descriptive statistics to evaluate differences in participant 
demographic and lifestyle variables by tuberculosis status and by obstruction/restrictive 
spirometry-based pattern. We used logistic regression to estimate the odds ratio [OR] for 
presence of obstruction/restrictive pattern and respiratory symptoms by tuberculosis 
status, and linear regression to assess the mean difference of spirometric measurements 
by tuberculosis status. Effect modification of the association between active tuberculosis 
and lung outcomes was evaluated in fully adjusted models by including an interaction 
term for active tuberculosis status with indicator variables for sex (male/female), age 
(<59.9 years/ ≥59.9), smoking status (never/ former/ current), BMI (<25 kg/m2/ ≥25 - 
<30/ ≥30), diabetes (yes/no), and arsenic (tertile: ≤6.0, 6.1-11.9, ≥12.0, µg/g). P values 
for interactions were obtained using Wald test for multiple coefficients. For the additional 
analysis, we estimated the odds ratio of active tuberculosis by urinary arsenic modeled as 
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a categorical variable, comparing tertiles of arsenic exposure, and as a continuous 
variable to compare an IQR increase of log urinary arsenic. P values for trend were 
obtained from modelling log-arsenic as continuous. All analyses were performed using 




Fourteen percent of participants (344/2,463) had a history of active tuberculosis. 
Participants with a history of active tuberculosis were more likely to be older (mean 
[IQR]) (60.8 [55.5 – 66.8] years vs. 58.5 [53.0 – 65.3] years) and completed a lower level 
of education (no high school: 19.5% vs. 16.8%) (Table 1) compared to those without 
active tuberculosis. Those with versus those without a history of active tuberculosis had a 
lower FEV1 % predicted (mean [IQR]) (88.5 [75.5 – 100.7] vs. 94.1 [82.2 – 104.8]), 
FVC % predicted (91.1 [78.3 – 100.7] vs. 94.4 [83.3 – 105.3]), and FEV1/FVC% (75.6 
[69.0 – 80.6] vs. 76.7 [71.5 – 80.1]). Those with a history of active tuberculosis were 
more likely to report presence of usual cough, frequent cough, production of phlegm with 
cough, and needing to stop for breath while walking for a few minutes (Table 1). 
 
Using the fixed-ratio definition (FEV1/FVC<0.70), airway obstruction was 
present in 21.2% (521/2,463) overall (Table 2) and in 27.3% of those with active 
tuberculosis history (Table 1). A spirometric based restrictive pattern was present in 
15.0% (369/2,463) overall and in 18.6% of those with active tuberculosis; the prevalence 
of diabetes in those with restriction was 68.0% (Table 2). Using the lower limit of normal 
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definition (FEV1/FVC <LLN), obstruction was present in 6.7% (141/2,463) overall and 
in 9.6% of those with active tuberculosis; spirometric restriction was present in 7.0% 
(148/2,463) overall and in 8.7% of those with active tuberculosis (Table 1). 
After full adjustment (Table 3, model 3), the odds ratio [95% CI] comparing those 
with a history of active tuberculosis to those without was 1.45 [1.08, 1.95] for obstruction 
and 1.73 [1.24, 2.40] for spirometric restrictive pattern (Table 3). When the lower limit of 
normal definition was used, the OR for was non-significant for obstruction (1.24 [0.81, 
1.89]) and non-significant for spirometric restrictive pattern (1.47 [0.97, 2.29]) (Table 3), 
although the direction of the association was consistent with the findings based on the 
fixed ratio definitions. 
The mean difference [95% CI] for FEV1 % predicted comparing active 
tuberculosis cases to those free of active tuberculosis was -5.84 [-7.91, -3.77]. For FVC 
% predicted, the mean difference was -5.23 [-7.45, -3.39] (Table 4). Amongst the normal 
group (FEV1/FVC >0.70 & FVC >80% predicted), both FEV1 % predicted and FVC % 
predicted remained significantly reduced in those with a history of active tuberculosis. 
No association was seen between a history of active tuberculosis and FEV1/FVC. 
A history of active tuberculosis was associated with self-reported respiratory 
symptoms at Visit 2: cough (OR [95%CI]) (1.43 [1.10, 1.87]; p=0.008) and production of 
phlegm when coughing (1.64 [1.21, 2.22]; p=0.001) (Table 5). A history of active 
tuberculosis was not significantly associated with frequent cough (4-6x/day), stopping for 




We found no effect modification for the association of prior active tuberculosis 
with airflow obstruction or spirometric restriction by sex, age, diabetes, or BMI (Figure 
1). By smoking status, effect modification was significant for a spirometric restrictive 
pattern (P-interaction=0.04) with the association being markedly stronger among former 
smokers (OR [95%CI]) (3.01 [1.77, 5.13]).  
 
Additional analysis of arsenic and tuberculosis 
For airflow obstruction and spirometric restrictive pattern, the association with 
prior active tuberculosis became slightly stronger when models were additionally 
adjusted for arsenic when using the fixed-ratio (obstruction: 1.47 [1.07, 2.02]) 
(restriction: 1.90 [1.34, 2.70]) (Table 3, model 4). When using the LLN, results remained 
non-significant. 
By arsenic exposure tertile, effect modification was statistically significant for the 
spirometric restrictive pattern  (P-interaction=0.03) with stronger odds ratios for those in 
arsenic tertile 2 (2.70 [1.44, 5.10]) and tertile 3 (2.63 [1.39, 4.99]) compared to tertile 1 
(1.17 [0.60, 2.28]) (Figure 1). No interaction was observed between arsenic and prior 
active tuberculosis for obstruction (P-interaction=0.2), although a stronger association 
between prior active tuberculosis and obstruction was observed among those in the 
highest arsenic tertile (2.27 [1.28, 4.05]).  
For FEV1 % predicted, the mean difference (95%CI) comparing those with and 
without a history of active tuberculosis was further reduced with each increasing arsenic 
exposure tertile, with the largest reduction in those highest exposed (-3.32 [-7.02, 0.39]%, 
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-5.97 [-9.91, -2.04]%, -8.86 [-13.08, -4.64]% for tertiles 1, 2 and 3 respectively) (Figure 
2). The same pattern was seen for FVC % predicted (-3.93 [-7.19, -0.66]%, -6.27 [-10.36, 
-2.19]%, -6.48 [-10.64, -2.32]%, respectively). However, the interaction was not 
statistically significant for either FEV1 % predicted or FVC % predicted. 
Arsenic exposure was significantly associated with a reduced odds of a past active 
tuberculosis diagnosis (Table 6). In fully adjusted models, the odds ratio [95% CI] 




From our findings, lung function and respiratory symptoms cough and cough with 
phlegm appear worse in participants who had a history of active tuberculosis compared to 
those who did not. A history of active tuberculosis was associated with reduced FEV1 % 
predicted and FVC % predicted and increased odds of airflow obstruction and a 
spirometric restrictive pattern, with a stronger association with the restrictive pattern, 
when based on the fixed-ratio definition. The associations were significant after 
adjustment for diabetes and major risk factors, including smoking. While the interaction 
analysis was underpowered and none of the p-values reached significance, the effect 
estimates showed lower FEV1 % predicted and lower FVC % predicted with preserved 
FEV1/FVC ratio comparing tuberculosis to no tuberculosis among those with arsenic 
levels in highest (>12.0 µg/L) compared to lowest tertile (≤6.0 µg/L). 
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Our findings support existing knowledge that a history of active tuberculosis is a 
risk factor for long-term respiratory impairment.4 An increasing number of population-
based studies have shown a consistent positive association between a history of active 
tuberculosis and the presence of airflow obstruction, with a recent meta-analysis finding a 
history of active tuberculosis to be associated with chronic obstructive pulmonary disease 
in adults over 40 years of age (pooled odds ratio 3.05 [242, 3.85]).21 A study of 14,050 
adults from 18 countries found that a history of self-reported tuberculosis increased risk 
for airflow obstruction (adjusted odds ratio 2.51 [1.83, 3.42] using the LLN definition).22 
The study also found an association with spirometric restriction (2.13 [1.42, 3.19]). In our 
study, the associations with the study outcomes based on the LLN were not statistically 
significant, possibly because of the smaller number of cases and a lack of power. The 
Global Initiative for Obstructive Lung Disease (GOLD) threshold of <0.70 for 
FEV1/FVC is thought to often misclassify normal spirometry as airflow obstruction in 
non-smokers, particularly in older adults.23 The American Thoracic Society recommends 
using the LLN instead of the fixed GOLD ratio. However, it is likely that the LLN misses 
individuals with mild airflow obstruction.24 In a population with a high burden of lung 
disease, as it appears to be in the SHS, underdiagnosis of obstruction may be a larger 
problem than overdiagnosis.25 Overall, however, why the associations are stronger with 
the ratio vs. LLN definition is unclear. 
Fewer studies have examined post-tuberculosis respiratory health in an 
indigenous population, with none in an American Indian population. One descriptive 
study (N=121) examined respiratory health post-tuberculosis, comparing indigenous to 
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non-indigenous people from Brazil, and found a high prevalence of respiratory 
symptoms, obstruction, and obstruction with reduced FVC in both groups.26  
It is proposed that the chronic inflammatory response and long-term anatomic 
alterations induced by pulmonary tuberculosis are the main pathological basis for long-
term impairment of lung function.27 A number of mechanisms may account for the 
development of airflow obstruction after pulmonary tuberculosis infection, including the 
structural damage of large and small airways including bronchiolar narrowing and 
bronchiolitis obliterans resulting from peribronchial fibrosis as well as accelerated 
emphysematous change caused by residual chronic or recurrent inflammation.28, 29 
Restriction in tuberculosis patients may be explained by structural changes in the lung as 
a result from aberrant lung tissue repair, such as bronchovascular distortion, fibrotic 
bands, and pleural thickening.4 There also could be significant overlap of obstruction and 
restrictive impairment mechanisms in those with tuberculosis, with some researchers 
suggesting that immune mediators and pathways that drive caseous necrosis and 
pulmonary cavitation, which can lead to airflow obstruction, during the disease may also 
set up for later fibrosis.4 Rather than a direct toxic effect of arsenic on the lung, an 
inflammation-mediated immunologic basis has been suggested,30 as arsenic is known to 
alter key functions of the innate and adaptive immune system.31-34 In mice, exposure of 
low to moderate concentrations of arsenic in drinking water (10 – 100 µg/L) led to a 
decrease in immune gene expression and aberration in inflammatory protein expression,9, 
35 resulting in susceptibility to airway inflammation.10 Both arsenic36, 37 and tuberculosis21 
are known to be associated with increased risk of developing bronchiectasis, suggesting 
some potential common pathophysiology for the long-term impact of arsenic and 
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tuberculosis on lung disease. In both tuberculosis-associated lung injury and arsenic-
induced effects on airway physiology, matrix metalloproteinases (MMPs), degradation 
enzymes, are likely central; MMPs can promote different stages of lung remodeling 
during tuberculosis including promoting alveolar destruction38 and, in arsenic-exposed 
individuals, MMP-9 impairs repair mechanisms in human lung epithelial cells.39  
In the additional analysis, the effect estimates for the association between history 
of tuberculosis and lung function indices FEV1 % predicted and FVC % predicted were 
progressively decreased by increasing urinary arsenic concentrations, however the p-
values for interaction were not statistically significant. Despite this dose-response, 
elevated arsenic exposure was unexpectedly associated with reduced odds of a history of 
active tuberculosis. This is inconsistent with the one previous study also examining this 
relationship, an ecological study from Chile, which found increased mortality from 
pulmonary tuberculosis associated with arsenic in drinking water.8 We hypothesize that 
our findings may be due to survival bias. For example, those with more severe 
tuberculosis may have died prior to participation in the SHS. It is also possible those with 
higher arsenic exposure were more likely to progress from latent to active tuberculosis, 
or, at the time of active tuberculosis development, also had higher risk of death. We were 
not able to determine if arsenic could have increased the incidence of active tuberculosis 
or increased mortality among infected individuals. Relevant to this population, older age, 
diabetes, and chronic obstructive pulmonary disease have been associated with an 
increased risk of death during tuberculosis treatment.40 In these scenarios, our sample of 
tuberculosis patients could be over-representing those with  better survival after 
treatment, including participants with lower arsenic exposure. This could have attenuated 
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effect estimates, undervaluing the relationship between tuberculosis and arsenic 
exposure. Additionally, if the most severely affected tuberculosis patients were not 
included in the study, all effect estimates shown, including the main analyses and 
possible interaction with arsenic, could be underestimated.  
Being able to run analyses for both active tuberculosis and a positive tuberculosis 
diagnostic test (suggestive of latent tuberculosis) could have provided additional clarity 
into the relationship with lung health and with arsenic, potentially to help determine if 
there was an increased risk of tuberculosis activation in those with both latent 
tuberculosis and higher arsenic exposure. This could help us assess arsenic’s contribution 
to pulmonary impairment through tuberculosis activation. A commonality among the 
majority of risk factors for tuberculosis activation, like HIV and malnutrition, is an 
impaired immune response.41 Part of the toxic effects of arsenic is likely through acting 
as an immunosuppressant42 and producing a state which favors opportunistic infections,43 
like tuberculosis. Animal studies have demonstrated immune suppression that is 
suspected to affect the pulmonary defense system,44 and studies in children have shown 
associations between increased urinary arsenic and reduced proliferative response to 
mitogens, percentage of CD4 T cells and IL-2 secretion levels, suggesting 
immunosuppression.45 Our analyses are based on a clinical diagnosis of active 
tuberculosis and not the tuberculin skin test, the purified protein derivative (PPD) test, the 
available screening test at the time of the study visit. This is because the administration of 
the Bacille Calmette-Guerin (BCG) vaccine could have interfered with the interpretation 
of the PPD test, as those who have received the vaccination also test positive for the PPD 
skin test. The study population was part of a large BCG vaccination trial during 1935-
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1938, during which children and adults aged 1 month to 20 years who had normal chest 
radiographs received the BCG vaccine or placebo, with a considerable degree of 
protection found throughout the 60 years of follow-up;46 we did not have individual 
records of vaccination status. 
This study benefitted from several strengths. The SHS is a well-established cohort 
with high-quality laboratory methods, high participation retentions, standardized variable 
collection, and strong support from the communities involved. We had individual 
spirometric measures standardized to American Thoracic Society recommendations. We 
also had American Indian reference values derived from the SHS population, which 
allowed us to assess lung function against predicted values for better interpretation of 
results. However, the subgroup used to calculate predicted values did not exclude those 
with tuberculosis or high arsenic exposure.  
Our study has several limitations. Outcome misclassification could have occurred 
from inaccurate recall of symptom and use of symptom questionnaires based on yes/no 
answers, which might be difficult for participants to choose from compared to scale-
based questionnaires. Determination of prior active tuberculosis infection was dependent 
on the completeness and accuracy of medical records. If any information pertaining to 
tuberculosis was inadequately documented, it would have been missed in our analysis; 
however, as diagnosis of tuberculosis among American Indians has long been a major 
concern, misdiagnosis is thought unlikely.46 More importantly, even if some cases were 
missed, diagnosis based on laboratory test and the combination of a radiological criteria 
with tuberculosis treatment ensure the high specificity of the case definition. Although 
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we did not have confirmation whether the active tuberculosis was pulmonary or extra 
pulmonary, around 80% of active tuberculosis cases in American Indians in the United 
States are pulmonary;47 however this could have led to an underestimation of effect 
estimates for pulmonary tuberculosis, as the number of cases was likely slightly diluted 
by extrapulmonary cases. While we had no information on HIV infection, the strongest 
known risk factor for progressing latent tuberculosis infection to tuberculosis disease, the 
HIV infection among American Indian patients with active tuberculosis is comparatively 
low than for other racial/ethnic groups.47 Our study is cross-sectional and precludes us 
from drawing temporal conclusions. The diagnosis of active tuberculosis happened in the 
past and was based on medical records; we do not know when airflow obstruction or 
spirometric restriction developed and we cannot discount the possibility they were 
present prior to tuberculosis. Additionally, due to incomplete data collection for year of 
tuberculosis diagnosis, we were not able to use it with confidence in our analyses, further 
preventing us from examining temporality. We did not account for multiple comparisons, 
because while we examined two exposures (arsenic and tuberculosis) individually with 
each outcome, we were not interpreting the results separately. Rather, the multiple 
outcomes were not independent and provided complementary information as we 
examined several ways to assess the pattern of lung impairment (obstructive vs. 
restrictive), looking for patterns of associations with the study outcomes that allowed us 
to assess the contribution of tuberculosis and joint effect with arsenic. We lacked 
information on possible additional confounders, such as exposure to indoor air pollutants, 
including exposure to smoke from cooking fires or heating fuel, and dietary information, 
including consumption levels of marine fatty acids and fresh fruit and vegetables.48 
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Regarding socioeconomic status, we used education status which is a proxy commonly 
used by the SHS, but that might not completely capture study participants’ 
socioeconomic status.  
 
CONCLUSIONS 
A prior active tuberculosis diagnosis was associated with impaired pulmonary 
function, including airflow obstruction and a spirometric restrictive pattern, and 
respiratory symptoms among American Indians in the Strong Heart Study, a population 
historically at elevated risk for tuberculosis infection and disease. We also found 
suggestive evidence of a possible interaction between arsenic exposure and a history of 
active tuberculosis with worse lung function, especially spirometric restrictive-related 
outcomes. The possible interaction between arsenic and active tuberculosis, as well as the 
reduced odds of active tuberculosis associated with arsenic exposure, warrants further 











Table 1. Participant characteristics by cumulative prevalence of history of medical-
record tuberculosis (N=2,463) 
   






58.5 (53.0 – 65.3) 60.8 (55.5 – 66.8) 
Female 
 
1,274 (60.1%) 226 (65.7%) 
Education   
  No high school (HS) 356 (16.8%) 67 (19.5%) 
  Some HS 491 (23.2%) 97 (28.2%) 
  Completed HS or higher 
 
1,271 (60.0%) 180 (52.2%) 
BMI, kg/m2 30.1 (26.8 – 34.4) 30.0 (26.5 – 33.8) 
Waist circumference (cm)  105 (96 -114) 104 (95 – 114) 
% Body fat 36.1 (29.3 – 43.0) 37.1 (30.1 – 42.5) 
Diabetes 1,091 (51.5%) 187 (54.4%) 
   
Urine ∑As* 8.5 (5.1 – 14.0) 7.6 (5.0 – 12.9) 
  %iAs 7.5 (5.4 – 10.8) 7.6 (5.4 – 10.7) 
  %MMA 14.1 (10.9 – 17.6) 14.2 (11.1 – 18.2) 
  %DMA 
 
77.9 (71.9 – 82.8) 77.8 (71.7 – 82.9) 
Smoking status   
  Never 640 (30.2%) 100 (29.1%) 
  Former 741 (35.0%) 115 (33.4%) 
  Current 
 
738 (34.8%) 129 (37.5%) 
Cigarette pack years 3 (0 – 18) 3 (0 – 16.5) 
   
FEV1, mL 2.5 (2.1 – 3.0) 2.3 (1.8 – 2.8) 
FVC, mL 3.3 (2.7 – 4.0) 3.0 (2.4 – 3.8) 
FEV1:FVC ratio, % 76.7 (71.5 – 80.1) 75.6 (69.0 – 80.6) 
   
% Predicted   
   FEV1 94.1 (82.2 – 104.8) 88.5 (75.5 – 100.7) 
   FVC 94.4 (83.3 – 105.3) 91.1 (78.3 – 100.7) 
   
Airflow obstruction (fixed) 427 (20.2%) 94 (27.3%) 
Airflow obstruction (LLN) 141 (6.7%) 33 (9.6%) 
Restrictive pattern (fixed) 305 (14.4%) 64 (18.6%) 
Restrictive pattern (LLN) 148 (7.0%) 30 (8.7%) 
   
Self-reported cough 451 (21.3%) 98 (28.5%) 
Cough 4-6x/week 286 (13.5%) 59 (17.2%) 
Phlegm with cough 276 (13.1%) 70 (20.4%) 
Shortness of breath 959 (45.8%) 171 (50.3%) 
Stopping for breath 332 (15.9%) 75 (22.1%) 
Data are median (interquartile range) or n (% of column) 
*µg/g creatinine; ∑As = inorganic arsenic plus methylated species 






Table 2. Participant characteristics by airflow obstruction and spirometric 












FEV1/FVC >0.70  




FEV1/FVC >0.70  




63.5 (56.7 – 69.7) 59.8 (54.1 – 65.7) 57.2 (52.3 – 63.8) 
Female 
 
256 (50.9%) 246 (66.7%) 998 (63.5%) 
Education    
  No high school (HS) 134 (25.7%) 80 (21.7%) 209 (13.3%) 
  Some HS 132 (25.3%) 94 (25.5%) 362 (23.0%) 
  Completed HS or higher 
 
255 (48.9%) 194 (52.7%) 1,002 (63.7%) 
Smoking status    
  Never 122 (23.4%) 121 (32.8%) 491 (31.6%) 
  Former 170 (32.6%) 131 (35.5%) 555 (35.3%) 
  Current 
 
229 (44.0%) 117 (31.7%) 521 (33.1%) 
Smoking pack years 
 
9.0 (0 – 33.0) 3.0 (0 – 15.0) 2.0 (0 – 14.0) 
BMI, kg/m2 
 
28.1 (25.0 – 31.9) 31.6 (27.9 – 36.3) 30.5 (27.3 – 34.4) 
Diabetes 
 
231 (44.3%) 251 (68.0%) 796 (50.6%) 
Urine ∑As, µg/g creatinine* 10.1 (5.7 – 14.6) 9.1 (5.1 – 16.2) 7.8 (4.9 – 13.0) 
    
FEV1, %predicted 79.9 (63.9 – 93.8) 75.2 (69.3 – 80.8) 99.2 (91.8 – 108.5) 
FVC, %predicted 95.5 (79.2 – 108.6) 72.0 (65.7 – 76.9) 97.4 (89.7 – 106.3) 
FEV1/FVC, % 65.2 (58.7 – 68.1) 80.5 (76.3 – 85.3) 77.9 (74.8 – 81.3) 
    
Self-reported symptoms    
Cough 155 (29.8%) 101 (27.5%) 293 (18.7%) 
Cough 4-6x/week 105 (20.2%) 63 (17.2%) 177 (11.3%) 
Phlegm with cough 101 (19.4%) 60 (16.4%) 185 (11.8%) 
Shortness of breath 255 (49.4%) 197 (55.0%) 678 (43.5%) 
Stopping for breath 113 (21.9%) 80 (22.5%) 214 (13.8%) 
    
History of active tuberculosis 94 (18.0%) 64 (17.3%) 186 (11.8%) 
All analyses are weighted. Data are n (% of column), or median (interquartile range) 


















Table 3. Odds ratio (95% confidence interval) of airflow obstruction and 
spirometric restrictive pattern by history of active tuberculosis 
 







427/1,387 94/186  
  Model 1 1.00 (Ref) 1.43 (1.07, 1.91) 0.02 
  Model 2 1.00 (Ref) 1.47 (1.09, 1.97) 0.01 
  Model 3 1.00 (Ref) 1.45 (1.08, 1.95) 0.01 
  Model 4 1.00 (Ref) 1.47 (1.07, 2.02) 0.02 
    
Obstruction† Lower limit of 
normal/ 
ControlΩ 
141/1,830 33/281  
  Model 1 1.00 (Ref) 1.28 (0.85, 1.92) 0.24 
  Model 2 1.00 (Ref) 1.28 (0.84, 1.94) 0.25 
  Model 3 1.00 (Ref) 1.24 (0.81, 1.89) 0.33 
  Model 4 1.00 (Ref) 1.27 (0.80, 2.00) 0.31 
    
Restrictiveα Fixed-ratio/  
ControlΩ 
305/1,387 64/186  
  Model 1 1.00 (Ref) 1.72 (1.25, 2.37) 0.001 
  Model 2 1.00 (Ref) 1.73 (1.25, 2.39) 0.001 
  Model 3 1.00 (Ref) 1.73 (1.24, 2.40) 0.001 
  Model 4 1.00 (Ref) 1.90 (1.34, 2.70) <0.001 
    
Restrictiveα Lower limit of normal/ 
ControlΩ 
148/1,830 30/281  
  Model 1 1.00 (Ref) 1.53 (1.00, 2.34) 0.05 
  Model 2 1.00 (Ref) 1.52 (0.99, 2.33) 0.05 
  Model 3 1.00 (Ref) 1.47 (0.97, 2.29) 0.07 
  Model 4 1.00 (Ref) 1.38 (0.86, 2.22) 0.19 
† Fixed airflow obstruction:  
Fixed-ratio: FEV1/FVC <0.70 
Lower limit of normal: FEV1/FVC <LLN 
α Restrictive pattern:  
Fixed-ratio: FEV1/FVC >0.70 & FVC <80% predicted 
 Lower limit of normal: FEV1/FVC >LLN & FVC <LLN 
Ω Control:  
Fixed-ratio: FEV1/FVC >0.70 & FVC >80% predicted 
Lower limit of normal: FEV1/FVC >LLN and FVC >LLN 
 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for BMI, waist circumference, percent body fat, diabetes 












Table 4. Mean difference (95% Confidence Interval) of lung function measures 




N Mean difference 
(95%CI) 
P-value 
FEV1, % predicted    
All 2,462 -5.84 (-7.91, -3.77) <0.001 
  Healthy α 1,573 -2.73 (-4.64, -0.83) 0.005 
    
FVC, % predicted    
All 2,462 -5.23 (-7.45, -3.39) <0.001 
  Healthy α 1,573 -2.70 (-4.51, -0.89) 0.004 
    
FEV1/FVC ratio 
(%) 
   
All 2,462 -0.43 (-1.40, 0.54) 0.38 
  Healthy α 1,573 -0.04 (-0.71, 0.64) 0.92 
α Healthy: FEV1/FVC >0.70 & FVC >80% predicted 








































Table 5. Odds ratio (95% Confidence Interval) of self-reported respiratory 




No tuberculosis Tuberculosis P-value 
Cough/No cough*  451/1,663 98/246  
  Model 1 1.00 (Ref) 1.41 (1.09, 1.83) 0.01 
  Model 2 1.00 (Ref) 1.44 (1.10, 1.88) 0.007 
  Model 3 1.00 (Ref) 1.44 (1.11, 1.88) 0.007 
  Model 4 1.00 (Ref) 1.43 (1.10, 1.87) 0.008 
  Model 5 1.00 (Ref) 1.34 (1.01, 1.79) 0.04 
 







  Model 1 1.00 (Ref) 1.29 (0.94, 1.76) 0.11 
  Model 2 1.00 (Ref) 1.31 (0.95, 1.80) 0.10 
  Model 3 1.00 (Ref) 1.32 (0.96, 1.82) 0.09 
  Model 4 1.00 (Ref) 1.31 (0.95, 1.81) 0.10 
  Model 5 1.00 (Ref) 1.22 (0.86, 1.71) 0.26 
    
Phlegm/No phlegm†  276/1,836 70/274  
  Model 1 1.00 (Ref) 1.59 (1.19, 2.14) 0.002 
  Model 2 1.00 (Ref) 1.63 (1.21, 2.21) 0.001 
  Model 3 1.00 (Ref) 1.65 (1.22, 2.23) 0.001 
  Model 4 1.00 (Ref) 1.64 (1.21, 2.22) 0.001 
  Model 5 1.00 (Ref) 1.53 (1.10, 2.11) 0.01 
    
Shortness of breath/No‡  959/1,134 171/169  
  Model 1 1.00 (Ref) 1.08 (0.86, 1.37) 0.50 
  Model 2 1.00 (Ref) 1.09 (0.86, 1.39) 0.46 
  Model 3 1.00 (Ref) 1.12 (0.88, 1.43) 0.35 
  Model 4 1.00 (Ref) 1.12 (0.88, 1.43) 0.36 
  Model 5 1.00 (Ref) 1.13 (0.87, 1.46) 0.37 
 







  Model 1 1.00 (Ref) 1.28 (0.95, 1.72) 0.10 
  Model 2 1.00 (Ref) 1.30 (0.97, 1.75) 0.08 
  Model 3 1.00 (Ref) 1.34 (0.99, 1.80) 0.05 
  Model 4 1.00 (Ref) 1.33 (0.99, 1.80) 0.06 
  Model 5 1.00 (Ref) 1.35 (0.98, 1.86) 0.07 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for BMI, waist circumference, percent body fat 
Model 4: further adjusted for diabetes 
Model 5: further adjusted for arsenic 
**Do you usually have a cough? 
∆Do you usually cough as much as 4-6 times/day, 4 or more days/week? 
†Do you usually bring up phlegm when you cough? 
‡Are you troubled by shortness of breath when hurrying on the level or walking up a slight hill? 










Table 6. Odds ratio (95% Confidence Interval) of history of tuberculosis by urinary 
arsenic concentration*  
 
 Inorganic Plus Methylated Arsenic Species µg/g 
creatinine 
 















No tuberculosis  
111/606 100/625 88/608 299/1,839  
  Model 1 1.00 (Ref) 0.71 (0.52, 0.97) 0.61 (0.43, 0.88) 0.74 (0.59, 0.92) 0.007 
  Model 2 1.00 (Ref) 0.71 (0.52, 0.97) 0.61 (0.43, 0.87) 0.73 (0.59, 0.91) 0.006 
  Model 3 1.00 (Ref) 0.71 (0.52, 0.96) 0.59 (0.41, 0.85) 0.72 (0.57, 0.90) 0.004 
  Model 4 1.00 (Ref) 0.70 (0.51, 0.96) 0.58 (0.41, 0.84) 0.71 (0.56, 0.89) 0.003 
*Tertiles are range; calculated based on overall population; sum of iAs, MMA, DMA µg/g creatinine 
**P-trend calculated modeling log-arsenic as continuous 
‡ Comparison of the 75th and 25th percentiles (interquartile range) of urinary arsenic concentrations (14.3 vs. 5.1 µg/g 
creatinine) 
Model 1: adjusted for age, sex, education, site 
Model 2: further adjusted for smoking status and smoking pack-year 
Model 3: further adjusted for BMI, waist circumference, percent body fat 















Figure 1. Odds ratio (95% confidence interval) for airflow obstruction and 
restrictive pattern (fixed-ratio) when history of tuberculosis is compared across 






*ORs were stratified by each subgroup of interest, and associated P values for interaction were obtained 
from models with interaction terms and using Wald tests for multiple coefficients 
Age= mean 
Adjusted for: age, sex, education, location, smoking status, cigarette pack-year, BMI, waist circumference, 
% body fat, and diabetes. 
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Figure 2. Mean difference (95% confidence interval) of lung function (FEV1, FVC 
percent predicted) by tuberculosis and urine arsenic tertile 
 
 
Adjusted for: age, sex, education, location, smoking status, cigarette pack-year, BMI, waist circumference, 
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Elevated exposure to arsenic disproportionately affects populations relying on private 
well water in the United States (US). This includes many American Indian (AI) 
communities where naturally occurring arsenic is often above 10 µg/L, the current US 
Environmental Protection Agency safety standard. The Strong Heart Water Study is a 
randomized controlled trial aiming to reduce arsenic exposure to private well water users 
in AI communities in North Dakota and South Dakota. In preparation for this 
intervention, 371 households were included in a community water arsenic testing 
program to identify households with arsenic ≥10 µg/L by inductively coupled plasma 
mass spectrometry (ICP-MS). Arsenic ≥10 µg/L was found in 97/371 (26.1%) 
households; median water arsenic concentration was 6.3 µg/L, ranging from <1 to 198 
µg/L. Silica was identified as a water quality parameter that could impact the efficacy of 
arsenic removal devices to be installed. A low-range field rapid arsenic testing kit 
evaluated in a small number of households was found to have low accuracy; therefore, 
not an option for the screening of affected households in this setting. In a pilot study of 
the effectiveness of a point-of-use adsorptive media water filtration device for arsenic 
removal, all devices installed removed arsenic below 1 µg/L at both installation and 9 
months post-installation. This study identified a relatively high burden of arsenic in AI 
study communities as well as an effective water filtration device to reduce arsenic in 
these communities. The long-term efficacy of a community-based arsenic mitigation 
program in reducing arsenic exposure and preventing arsenic related disease is being 





In the United States, the estimated population using domestic wells for drinking 
water with arsenic (As) levels above the Environmental Protection Agency (EPA) 
maximum contaminant level (MCL) of 10 µg/L is 2.1 million people 1, with an additional 
384,000 people exposed through public water systems 2. Arsenic is a highly toxic and 
carcinogenic element, classified by the US Agency for Toxic Substances and Disease 
Registry as the top substance on its priority list of hazardous substances 3. Millions more 
are exposed to arsenic in drinking water below the MCL, which is of concern as the 
evidence suggests no safe threshold exists 4. Increasing evidence supports the role of low-
moderate arsenic (<50 µg/L) in cancer and cardiovascular disease, and potentially 
diabetes, neurodevelopmental toxicity, immune effects and nonmalignant respiratory 
disease 5. 
Private wells do not fall under the jurisdiction of the EPA’s Safe Drinking Water 
Act, and it is the responsibility of the well owner to make sure their water is safe. Major 
barriers to arsenic water testing include general awareness, geographic distance to a 
laboratory and lack of access to water testing 6, and the high price point per test (~20 
USD per sample) 7-9. Rural and suburban families relying on ground water, including 
many in American Indian (AI) communities, are the most affected, especially in the 
Southwest, Midwest and Northeast US 10. The concentration of naturally occurring 
arsenic in ground water varies regionally due to a combination of climate and geology, 
with greater concentrations found in certain areas of the US including the Interior 
Plains.11 In AIs who participated in the Strong Heart Study (SHS), an ongoing cohort 
study of cardiovascular disease and its risk factors among AIs, arsenic has been 
75 
 
associated with an increased risk of cardiovascular disease, diabetes, kidney disease, and 
some cancers 12-14, highlighting the urgency of preventing arsenic exposure for those 
relying on private wells.  
The Strong Heart Water Study (SHWS), the first randomized controlled trial of an 
arsenic intervention in the US, was developed to reduce arsenic exposure in AI 
communities in North Dakota and South Dakota. High arsenic in ground water in aquifers 
composed of felsic volcanic rocks is found in these areas.11 All participating households 
receive a point-of-use filter to remove arsenic from drinking and cooking water and are 
randomly assigned to receive an intensive health promotion program or the standard 
program. In preparation for the intervention, a water quality assessment was performed 
between February 2014 and January 2018 to achieve the following objectives: (1) to 
identify households with private wells with elevated arsenic that are eligible for the 
SHWS using inductive coupled plasma mass spectrometry (ICP-MS); (2) to assess water 
quality parameters that could interfere with the efficacy of the point-of-use adsorptive 
media filter and (sub-objective 1) to evaluate the accuracy of the Arsenic Econo-Quick™ 
(Industrial Test Systems, Inc.) test as a potential rapid screening tool for eligible 
households; and (3) to evaluate the efficacy of the selected point-of-use adsorptive media 
filter in study households.  
 
METHODS 
Study Area and Private Well Testing  
The study area consists of households using private wells for drinking water in 
three Tribal Nations in South Dakota and North Dakota, communities referred to as A, B, 
76 
 
and C (as requested by the communities which prefer their names are not made public). 
Convenience sampling was performed by study team members to test domestic wells 
from 2014 to 2018 (N=371). Strategies used to identify those homes included word of 
mouth, health fairs, radio, community member contacts, and a database of previously 
tested wells. In November 2015, a more detailed water quality assessment was performed 
in 29 households, chosen by convenience sampling and willingness to participate. Of 
those 29 households, 19 had also been tested for arsenic in February/March 2014, 
allowing the examination of arsenic temporality in the study area.  
 
Water Sample Collection  
Water samples were collected from the kitchen faucet using a sampling and 
analysis plan developed from EPA guidelines 15. Water sampling locations were 
determined by a handheld GPS (Global Positioning System) navigator (Garmin eTrex 
10). Water samples for ICP-MS arsenic testing (Objective 1) were collected in 20 mL 
scintillation vials. Duplicate samples were collected from each well, however only one 
sample has been analyzed from each well to date. For detailed water quality analyses 
(Objective 2), acid-washed 125mL plastic bottles were used to collect filtered samples for 
iron and phosphorus testing; non-acid-washed bottles to collect samples for alkalinity, 
sulfate, and silica; a non-acid-washed bottle to collect filtered samples for nitrate; a 20 
mL scintillation vial to collect samples for arsenic, uranium, lead, and cadmium for ICP-
MS analysis; arsenic speciation filters to collect samples for ICP-MS As(III) analysis; 
and a multi-parameter water quality sonde (YSI Inc./Xylem Inc.) to test for pH. To test a 
rapid water arsenic screening kit (Objective 3), water samples were collected in an acid-
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washed plastic beaker and then poured into reaction bottles (clear PVC) supplied in the 
arsenic testing kits.  
 
Objective 1: ICP-MS Testing of 342 Households in the Study Area for Arsenic  ≥10 
µg/L (2014-2018) 
Water samples (n= 342) were transported to Mid Continent Testing Labs, Inc. 
(Rapid City, South Dakota) for ICP-MS arsenic analysis. The number of samples tested 
by Mid Continent per community was 319, 15, and 8 in communities A, B and C, 
respectively from 2014 to 2018. The larger number of samples in Community A is related 
to more extensive sampling in Community A, which is the focus of the SHWS 
intervention. The quality assurance program employed by the laboratory has a variety of 
checks to ensure accuracy of results. Prior to each day’s use, the ICP-MS was run 
through an optimization and mass calibration, selecting the optimum instrument 
parameters for the day. The instrument was calibrated by testing various standards, in the 
case of arsenic analysis, using 2, 5, 10, 20, and 100 ppb standard solutions. The 
calibration was then checked on two 50 ppb stock solutions. The first is the Initial 
Calibration Verification (ICV), prepared from a different source from the calibration 
standards. The second is the Continuing Calibration Verification (CCV), prepared from 
the same source as the calibration standards. Both must show a value of 50 ppb, within 
+/-10% of expected value. The CCV was checked at least every 10 samples tested 
throughout the day. A blank DI solution was also checked, the Initial Calibration Blank 
(ICB). Mid Continent also uses a Matrix Spike and a Matrix Spike Duplicate to ensure 
accuracy. At least every 10 samples, a small concentration of arsenic, 25 ppb, was added 
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to two aliquots of the sample, and should get 90-110% recovery from the spiked samples. 
For any samples that are digested, the lab also carries a Blank and Fortified Blank 
through the process to demonstrate proper recovery and lack of sample contamination 
through digestion. During all calibration and sample testing, a constant flow of small 
amounts of internal standards, rare earth elements, were injected into the solutions being 
tested. These values needed to stay within a certain range and help prove there were no 
erroneous test results from matrix interference. All analyses were assessed to the 
laboratory detection limit less than or equal to 1 µg/L. Arsenic results were disseminated 
to study participants after ICP-MS testing was performed; participants were delivered a 
letter by a study team member with their signature as proof of receipt.  
 
Objective 2: Intensive Water Quality Assessment in 29 Households (2015) 
In addition to arsenic, the following additional water quality parameters were 
tested in 29 households in 2015: arsenic speciation, nitrate, iron, sulfate, phosphorus, 
alkalinity, silica, pH, uranium, cadmium, and lead. The testing parameters were selected 
based on historic Indian Health Service data and known compounds that interfere with 
filtration 16. Nitrate, iron, sulfate, phosphorus, alkalinity, and silica water samples were 
brought back to a semi-controlled temporary laboratory and tested on a Hach DR 2800 
portable spectrophotometer at the end of every sampling day. For silica samples that were 
over the limit of detection, a 1:100 dilution with deionized water was performed. Lead, 
uranium, cadmium, arsenic, and arsenic speciation water samples were stored at room 
temperature in a dry lab and shipped back to Johns Hopkins University Trace Metals 
Laboratory for ICP-MS analysis. The samples were acidified in a 1:1 dilution with 10% 
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optima grade HNO3 (Fisher Scientific, Columbia MD) and allowed to digest at room 
temperature for 48 hours. The acidified samples were diluted with 2% HNO3 and 0.5% 
HCl (Fisher Optima Trace Element Grade) in ultra-pure Milli-Q water and vortexed prior 
to analysis. A calibration curve for the element tested (As, Pb, Cd, U) was built using an 
appropriate element standard solution (Multi-element Aqueous CRM, QC Standard 21. 
VHG Labs, Manchester, NH, US). Ge, In and Bi were added as an internal standard (CPI 
International, Santa Rosa, CA, US) for samples and calibration curves to control potential 
drifts in the elements tested signal. All elements were analyzed using ICP-MS (Agilent 
7500ce Octopole ICP-MS, Agilent Technologies, Santa Clara, CA, US). For quality 
control purposes, a drinking water standard reference material was used (Standard B 
Water TMDW-B, High Purity Standards, Charleston, SC, US). The results of the QCs 
were within ±10% of the stated value. Ten-percent of reagent blanks and duplicates were 
also carried out for quality control. To measure the arsenic species arsenite (AsIII) and 
arsenate (AsV), syringe filters (Millipore PVDF Sterile Syringe Filter Unit, 0.45 Micron, 
33mm Diameter) and arsenic speciation cartridges (MetalSoft Center) were used. 
In sub-objective 1, arsenic rapid testing kits were chosen to be tested in 23 
households in 2015 because of their potential ability to inexpensively measure arsenic in 
drinking water in 12 minutes and identify affected households. The Econo-Quick™ test 
brand was selected because previous studies conducted found high accuracy 8, 17-21. Two 
Arsenic Econo-Quick™ test kits were evaluated: a low-range (<1 – >160 µg/L) (kit # 
481303) and high-range (0 – 1000 µg/L) (kit # 481298). The test utilizes a modified 
Gutzeit method: inorganic arsenic compounds present in water samples are converted to 
arsine gas which reacts with mercuric bromide on the test strip to form mixed mercury 
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halogens causing a color change from white to yellow or brown 21, 22. The test is 
qualitative, with the color intensity proportionally related to the arsenic concentration in 
the sample. The color on the test strip is visually compared against a colorimetric 
standard (Figure 1) by the tester. 
Even though recommended by the manufacturer, we did not use reagent #2 
because of health concerns due to potassium peroxymonosulfate and potassium 
peroxydisulfate, which may cause irritation to skin or eyes or breathing difficulties if 
inhaled 23, 24. The practice of removing reagent #2 has shown high accuracy in 
comparison to ICP-MS measurements previously in Bangladesh 25. To manage waste in 
the field, our research team separated the reagents from the liquid, once tests were 
completed, using a coffee filter over a 5-gallon plastic bucket 26, separating out the zinc 
and stopping production of hydrogen and arsine gases. The used filters were stored in a 
plastic bag for future hazardous waste disposal. One team member ran a high-range test 
and one team member ran a low-range test at each household, for a total of two tests per 
household. Testers were blinded to the results of the other.  
To assess for a potential batch effect of the rapid test kits, laboratory experiments 
were performed with arsenic-spiked samples of known concentrations using the same kits 
that were used in field experiments. Five samples of Milli-Q water were spiked with 
sodium arsenate dibasic heptahydrate to concentrations of: 1, 5, 10, 20, and 50 µg/L. The 
prepared samples were prepared under strict and well-established laboratory conditions 
but were not tested by ICP-MS. One tester, blinded to the arsenic levels, tested each of 





Objective 3: Efficacy of Point-of-use Filter in Study Households (2017-2018) 
The Multipure® (Model CB-As-SB, Las Vegas, NV) Drinking Water System is a 
point-of-use adsorptive media filter tested according to NSF/ANSI Standard 53 for the 
reduction of arsenic. The filter utilizes block carbon to remove arsenate (As(V)) and has a 
relatively high flowrate. It was installed in 6 households, a convenience sample, with 
water As> 10 µg/L as a pilot study in 2017. The system consists of a small filter faucet 
connection at the kitchen sink that is separate from the kitchen faucet that is used for 
washing dishes and other household tasks unrelated to drinking and cooking. The filters 
were monitored for nine months, with total water usage monitored and arsenic samples 
taken at installation and 9-month follow-up, to examine efficacy of reducing arsenic in 
the study setting and to determine filter life in proportion to the amount of water being 
used. 
 
Statistical Analysis  
Objective 1: Using the fishnet tool in ArcGIS 10.5.1 (ESRI, Redlands, CA), a 5-
mile by 5-mile grid of polygons was created for the three communities. The spatial join 
tool was used to connect the location of private wells to polygons in the grid. The 
averages of arsenic concentrations of wells within the same polygon was calculated for 
each polygon to anonymize wells. If a private well had been tested multiple times in the 
years 2014-2018, the highest arsenic concentration was used. For wells with arsenic 
concentrations below the detectable of 1 µg/L, 0.5 µg/L was used for the average 
82 
 
calculation. Polygons were shaded based on the range (<5 µg/L; 5 - <10 µg/L; or ≥10 
µg/L) in which the average fell.  
Objective 2: Descriptive statistics were shown for water parameters and stratified 
by community, and differences in those characteristics in water samples by arsenic 
concentration (<10 and ≥10 µg/L) using t-tests were compared. To estimate variability in 
arsenic levels in the subset of drinking water samples collected in 2014 and 2015, we 
estimated the intraclass correlation coefficient and used a paired t-test to estimate the 
mean difference between paired samples. We also estimated the Spearman’s rank 
correlation coefficient for descriptive purposes. Statistical analyses were performed using 
Stata software, version 13.1 (StataCorp, College Station, TX, USA). Sub-objective 1: 
Determining the accuracy of the rapid arsenic testing kit provides an estimate of its 
usefulness as a screening tool, the weighted average of a test’s sensitivity and specificity, 
where the sensitivity is weighted by prevalence and specificity is weighted by the 
complement of prevalence 27. The sensitivity of the rapid test, the true positive, is defined 
as the proportion of wells with elevated arsenic (10 µg/L) that are correctly identified by 
the rapid test. The specificity of the rapid test, the true negative, is defined as the 
proportion of wells that do not have elevated arsenic that are correctly identified as 
negative by the rapid test 28. Sensitivity and specificity were calculated by comparing 
rapid test results to ICP-MS, the reference method for arsenic assessment 8, 17, 19. 
Objective 3: Descriptive statistics were used to compare water As levels at 





Objective 1: Water Arsenic Levels 
Water arsenic was ≥10 µg/L in 97 (26.1%) households, between 5 - <10 µg/L in 
135 (36.4%) households, and <5 µg/L in 139 (37.5%) households, based on ICP-MS 
testing (Table 1, Figure 2). In Community A (n=330), 26.7% of households had water 
arsenic ≥10 µg/L, with median (interquartile range [range]) arsenic of 6.6 (4.5, 10.7 
[<1.0, 198.0]) µg/L; in Community C (n=17), 47.1% of households had water arsenic ≥10 
µg/L, with median arsenic 9.7 (3.1, 19.9 [<1.0, 30.1]) µg/L; and in Community B (n=24), 
1 household had water arsenic ≥10 µg/L, with median arsenic below the limit of detection 
(range [<1.0, 1.3]) µg/L. 
 
Objective 2: Detailed Water Quality Assessment in 29 Households 
Water arsenic was ≥10 µg/L in 37.9% (n=11) in the 29 households included in the 
water quality assessment, with a median (interquartile range [range]) of 6.3 (<1.0, 15.0 
[<1.0, 49.7]) µg/L arsenic overall (Table 2). All parameters were similar in samples with 
arsenic above and below 10 µg/L, except for sulfate which was borderline statistically 
higher in samples with lower arsenic concentrations (91.2 (lower arsenic) vs. 20.0 (higher 
arsenic) mg/L, p=0.07). Median silica was highest in Community A (194.4 mg/L), much 
higher than Community B (7.96 mg/L) (Supplemental table 1). Community A also had 
the highest median uranium level (6.4 µg/L) (Supplemental table 1). Uranium was at or 
above the MCL (30 µg/L) in three wells in the 2015 pilot, with two located in 
Community A. Median uranium level was higher in water samples with arsenic ≥10 vs. 
<10 µg/L (uranium 4.4 vs. 2.9 µg/L, p=0.89), but the difference was not statistically 
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significant (Table 2). Nitrate, iron, and cadmium medians were all below the EPA MCL 
and Secondary Drinking Water Standards. While lead was detectable in all three 
communities (highest median concentration in Community B (0.6 µg/L)), all samples 
were below the lead action level (EPA Treatment Technique) of 15 µg/L. For arsenic 
speciation, the mean percent of total arsenic that was arsenite (As(III)) was 5.0% in 
Community A and 38.2% in Community C (results not shown). We found some temporal 
variability of arsenic in wells (n=19) with ICC (95% confidence interval) of 0.77 (0.58, 
0.96) and paired mean difference (95%CI) of 3.50 (0.07, 6.92) µg/L higher arsenic in 
2014 vs. 2015 (Figure 3). The Spearman correlation coefficient between samples 
collected in 2014 and 2015 was r=0.86 (p= 0.05). 
In a field setting, the Arsenic Econo-Quick™ low-range test had 25.0% sensitivity 
and 100.0% specificity when compared to ICP-MS measurements relative to ≥10 µg/L, 
and the high-range test had 100.0% true positive rate and 8.3% true negative rate 
(Supplemental table 2 and Supplemental figure 1). In laboratory experiments with 
arsenic-spiked samples overall, the high-range test had moderate to high sensitivity 
(87.5%) and high specificity (100%); the low-range test had moderate sensitivity (62.5%) 
and high specificity (100%) (Supplemental table 3). The sensitivity was higher for both 
the high-range (100.0%) and low-range test (75.0%) when reagent 2 was not used. 
 
Objective 3: Adsorptive filter results 
The Multipure® filter effectively removed arsenic in each household, with arsenic 
found to be below the LOD (<1 µg/L) in water samples collected from each filter faucet 
at the installation and the 9-month follow-up timepoint (Figure 4). In the pilot 
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households, total water usage from the filter over 9 months ranged from 80 to 1,233 
gallons (median 330). Silica ranged from 21.5 to 32.4 mg/L (median 22.6) in kitchen 




Overall, a quarter of private wells tested in tribal communities in North and South 
Dakota had arsenic ≥10 µg/L, and therefore are eligible to participate in the SHWS, 
which will provide arsenic-safe drinking water to affected households. This is much 
higher than the national average of 7% of domestic well users in the US with arsenic ≥10 
µg/L 1. These findings are consistent with historic Indian Health Service data for the area 
and with urinary arsenic excretion patterns in Strong Heart Study participants 6, 
demonstrating that tribal communities in North Dakota and South Dakota are 
disproportionately exposed to arsenic in drinking water, especially in Communities A and 
C. Community C is undergoing the installation of a new public water system that will 
provide service to homes on private wells, including many of those tested in this water 
quality assessment. As such, the SHWS will focus on Community A, where homes often 
cannot be connected to community water systems, typically because of distance from the 
tribal water system line, and arsenic-safe drinking water is urgently needed. The 
Multipure® filter was found to be highly effective at lowering drinking and cooking 
water arsenic concentrations below 1 µg/L, even after consistent usage over 9 months. As 
a result, this point-of-use arsenic removal device will be used to reduce arsenic exposure 




Water Quality Parameters  
Silica was above the manufacturer’s recommended concentration for optimal 
filter performance (<30 mg/L) in 20 households out of 29 in the 2015 intensive water 
quality pilot and in 1 household out of 6 where the filter was installed29. High silica 
concentrations could reduce the amount of time the filter will effectively be able to 
remove arsenic, consequently increasing the frequency that the filter cartridge will need 
to be replaced.30 Our pilot study showed that the adsorptive media filter proposed for the 
SHWS effectively removed As for 9 months, indicating that the well with high silica in 
Community A did not affect the performance of the filter. Sulfate and iron can also 
potentially interfere with an adsorptive media water filter. However, the levels of sulfate 
and iron found at study communities were below the problem levels for both parameters 
(720 mg/L and 0.5 mg/L, respectively)16. The majority of inorganic arsenic in the study 
communities occurred as As(V), which is considered less toxic than As(III) 5. Reverse 
osmosis was not chosen as a treatment option, as treated water may substantially change 
the taste of household drinking water since during the treatment process inorganic 
compounds are removed, and during our formative research, community members 
expressed concern about certain water filters changing the taste of their drinking water. 
Another concern about reverse osmosis was the relatively low flow rate.  
 
Performance of the Rapid Arsenic Test 
The Arsenic Econo-Quick™ test performed poorly in our setting and cannot be 
used as a screening tool at our community sites. It was difficult to meet the required test 
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manufacturer conditions to conduct the test in the field. The manufacturer recommends 
water samples be warmed to 22 - 28°C before testing; air temperature is recommended to 
be in the same range 22. At our community site, water samples were not warmed upon 
collection, and tests were conducted outside in November (mean air temperature 8.3°C) 
31. However, a study in Peru with similar cold weather conditions using the same kit 
found the high-range test to be accurate 18. Another potential source of interference is 
sulfide. When reagent #2 was removed, our ability to mitigate any interference with 
sulfide was also removed. Sulfide concentrations at our community site were tested in 
February 2017 as part of the SHWS filter pilot; all sulfide levels were < 0.050 mg/L, 
below the 2 mg/L sulfide threshold the manufacturer reports causes interference. 
The rapid test needs to be used in a well-ventilated area due to the production of 
hydrogen and arsine gases, in addition to eye and hand protection 22. Disposal of waste 
presented a problem for team members while conducting field work, as both liquid waste 
and mercuric bromide testing strips needed to be properly handled. This is an additional 
concern in resource limited settings where waste disposal facilities are not available.  
 
Arsenic Temporality 
In the 19 households that had arsenic samples taken in both 2014 and 2015, 
findings suggest some temporal variability of the arsenic levels in groundwater over our 
one-year surveillance period, with levels being on average slightly lower in the 2nd 
period. Other studies have shown that the degree of temporal variability in groundwater 
arsenic is generally low 32, 33. The arsenic concentration variability that we found could 





The Multipure® filter effectively removed arsenic in each household that 
participated in the pilot study to below 1 µg/L at the 9-month follow-up, including one 
household that had elevated silica, and is an adequate water treatment intervention for the 
SHWS. For private well users, point-of-use filtration devices have been shown to be 
effective in removing arsenic from drinking water, and major challenges are consistent 
use of the filter and maintenance over time 35, 36. The SHWS engages community 
promoters to deliver messages on the importance of using the filter faucet for drinking 
and cooking, and to explain to households how to change the filter cartridge for their 
arsenic removal device. 
 
CONCLUSIONS 
This water quality assessment and pilot of a point-of-use arsenic removal device 
was important for informing the next steps of the Strong Heart Water Study, the first 
randomized controlled trial of a community based arsenic mitigation intervention in the 
US. We identified that arsenic above the current arsenic MCL in drinking water was 
relatively common, especially in communities A and C. We also found elevated silica, 
which could reduce the efficacy of a point-of-use arsenic absorptive media filter. The 
Arsenic Econo-Quick™ test, originally planned for use as a screening tool for recruitment 
of participants in the intervention, was found to have low performance in rural North 
Dakota and South Dakota. In our assessment of the effectiveness of the adsorptive media 
water filtration device for arsenic removal, all devices installed removed arsenic below 1 
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µg/L at both installation and 9 months post-installation. Through our water quality 
assessment, we identified a relatively high burden of arsenic as well as an effective water 
filtration device to reduce arsenic exposure in study communities. The long-term efficacy 
of a community-based arsenic mitigation program, including these arsenic removal 
devices in reducing arsenic exposure and preventing arsenic related disease, is being 


















Table 1. Water Arsenic (µg/L) in Domestic Wells in SHWS Tribal Nations in 
2014-2018 (N= 371) 
 All Community A Community B Community C 
N 371 330 24 17 
Median (IQR) 6.3 (4.0, 10.5) 6.6 (4.5, 10.7) <1.0* (<1.0*, <1.0*) 9.7 (3.1, 19.9) 
Range <1.0*, 198.0 <1.0*, 198.0 <1.0*, 1.3 <1.0*, 30.1 
Number of wells:     
  < 5 µg/L 139 111 (79.9%) 23 (16.5%) 5 (3.6%) 
  ≥ 5- <10 µg/L 135 131 (97.0%) 0  4 (3.0%) 
  ≥ 10 µg/L 97 88 (90.7%) 1 (1.0%) 8 (8.2%) 
















Table 2. Median Concentration (IQR) of Water Parameters Tested in 29 
Households Overall and by Water Arsenic Levels Above and Below 10 µg/L 





































0.0029           0.49 (0.15-0.42) 0.3 0.1 0.14 ICP-MS JHU Trace 










































0b 6.8 (6.5-7.1) 6.7 6.9 0.27 YSI field 
a Limit of detection (LOD) = LOD/2 (used in analyses) for undetectable samples;  
b Upper limit: phosphorus = 1.50 mg/L; silica = 1.60 mg/L; nitrate = 30.0 mg/L; sulfate = 150 mg/L; alkalinity = 
400 mg/L; iron = 6.0 mg/L; pH = 14 units 
c US Environmental Protection Agency’s National Primary Drinking Water Regulations, maximum contaminant 
level (MCL): arsenic = 0.010 mg/L; cadmium = 0.005 mg/L; lead = zero; uranium = zero; nitrate = 10 mg/L 
* P-value comparing difference in parameter between low and high arsenic. 









Figure 4.  Visual comparison of test strip from Arsenic Econo-Quick™ test against 


















Figure 5. Water Arsenic Samples from Household Private Wells in SHWS Tribal 
Nations from 2014-2018. The total number of samples was 330 in Community A, 24 in 
Community B, and 17 in Community C. The mean water arsenic concentrations were 
estimated in a 5-mile by 5-mile grid of polygons to anonymize wells. The number of 











Figure 6. Comparison of 2014 and 2015 ICP-MS arsenic measurements (n=19) in 
















ICC (95% CI):  
0.77 (0.58, 0.96) 
Paired mean 
difference (95% CI): 
3.50 (0.07, 6.92) µg/L 
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Figure 4. Arsenic concentration at baseline and 9-month follow-up with detection 







































Arsenic concentration at each study time point




Supplemental table 1S. Median (Interquartile Range) Concentration of Water 
Parameters by Community in 29 Households 
 Community A Community B Community C 
N 11 9 9 
Arsenic (µg/L) 11.4 (5.8, 16.1) 0.2 (0.2, 0.2) 11.4 (6.3, 22.3) 
Cadmium (µg/L) 0.01 (0.01, 0.01) 0.01 (0.01, 0.01) 0.01 (0.01, 0.01) 
Iron (µg/L) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 
Lead (µg/L) 0.2 (0.1, 0.3) 0.6 (0.3, 1.0) 0.2 (0.2, 0.3) 
Nitrate (mg/L) 0.9 (0.5, 1.4) 0.1 (0.1, 0.6) 0.1 (0.1, 0.1) 
Uranium (µg/L) 6.4 (3.4, 24.0) 0.3 (0.1, 2.7) 2.6 (0.9, 4.4) 
Phosphorus (mg/L) 0.03 (0.03, 0.03) 0.1 (0.08, 0.1) 0.06 (0.03, 0.1) 
Silica (mg/L) 194.4 (119.4, 274.1) 7.9 (4.7, 14.4) 107.2 (101.7, 124.9) 
Sulfate (mg/L) 20.0 (20.0, 143.0) 118.0 (20.0, 347.5) 47.9 (20.0, 140.0) 
pH 6.8 (6.5, 7.1) 6.6 (6.3, 7.2) 6.9 (6.5, 7.0) 























Supplemental table 2S. Accuracy of Rapid Test in Field Setting Compared to 
ICP-MS to Identify Samples ≥ 10 µg/L 






95% CI Accuracy 
Low-range test 
(N=22) 
     
   ≥10 µg/L 25.0% (2/8) 3.2 – 65.1% 100.0% (14/14) 76.8 - 100.0% 
72.7% 
(16/22) 
   ≥5 62.5% (5/8) 24.5 – 91.5% 92.9% (13/14) 66.1 – 99.8% 
81.8% 
(18/22) 





     
   ≥10  100.0% (7/7) 59.0 - 100.0% 8.3% (1/12) 0.0 - 26.5% 42.1% (8/19) 
*The true positive rate (sensitivity) is the ratio of true positive/(true positive+false negative).  































Supplemental table 3S. Accuracy of Rapid Test in Laboratory Setting to 
Identify Samples ≥ 10 µg/L 







Low-range test (N=16) 62.5% (5/8) 24.5 – 91.5 100.0% (8/8) 63.1 – 100.0 
     No reagent 2 (n=10) 75.0% (3/4) 19.4 – 99.4 100.0% (6/6) 54.1 – 100.0 
     With reagent 2 (n=6) 50.0% (2/4) 6.8 – 93.2 100.0% (2/2) 15.8 – 100.0 
High-range test (N=16) 87.5% (7/8) 47.4 – 99.7 100.0% (8/8) 63.1 – 100.0 
     No reagent 2 (n=10) 100.0% (4/4) 39.8 – 100.0 100.0% (6/6) 54.1 – 100.0 
     With reagent 2 (n=6) 75.0% (3/4) 19.4 – 99.4 100.0% (2/2) 15.8 – 100.0 
*The true positive rate (sensitivity) is the ratio of true positive/(true positive+false negative).  

























Supplemental figure 1S. Arsenic measurements by Rapid Tests in a Field 
Setting and by ICP-MS (N=41) 


















Summary of Findings 
The main objectives of this dissertation were to (1) evaluate the relationship 
between arsenic exposure and nonmalignant respiratory health in a population chronically 
exposed to low-moderate arsenic levels; (2) evaluate the impact of tuberculosis survival 
on lung function and its potential association with arsenic exposure in the Strong Heart 
Study; and (3) conduct water arsenic testing and a water quality assessment pilot for the 
Strong Heart Water Study. This dissertation attempted to examine the relationship 
between low-moderate arsenic exposure and respiratory outcomes given widespread 
exposure to arsenic through drinking water in the study population and the availability of 
multiple measures of respiratory health status. 
 In Chapter 1 we conducted multiple analyses using data from the Strong Heart 
Study (SHS) in order to examine the association between arsenic exposure and 
nonmalignant respiratory outcomes. We first evaluated differences in participant 
variables by spirometric obstruction and restrictive patterns and urinary arsenic tertile. 
We then estimated the odds ratio for the presence of an obstructive or restrictive pattern, 
using both the fixed-ratio and lower-limit of normal definitions, respiratory symptoms, 
and nonmalignant respiratory disease by urinary arsenic concentration. We also assessed 
the mean difference of FEV1, FVC, and FEV1/FVC using both % predicted values and 
crude mL values. In all models, we ran sensitivity analyses for outcomes by further 
adjusting for diabetes. We evaluated effect modification for the association of arsenic 
with obstruction and restrictive pattern by indicator variables for sex, age, smoking 
status, body mass index, and diabetes. We also evaluated arsenic metabolism by 
101 
 
examining the association between the relative proportions of arsenic species (iAs%, 
MMA% and DMA%) in urine per 5% change with the presence of an obstructive or 
restrictive pattern. Arsenic was associated with increased odds of fixed-ratio restrictive 
lung pattern, lower FEV1 and lower FVC (both % predicted and crude values), borderline 
associated with fixed-ratio obstruction, and not associated with FEV1/FVC. These 
findings support recent meta-analysis findings that low-level arsenic exposure is a 
restrictive lung disease risk factor. Urinary relative proportions of iAs, MMA, and DMA 
were not associated with an obstruction or restrictive pattern. Arsenic was associated with 
the symptom ‘stopping for breath while walking’ and with self-reported emphysema. 
However, in the sensitivity analyses, diabetes attenuated the association of arsenic with 
restrictive pattern suggesting the possibility that diabetes could be in the causal pathway 
between arsenic and restrictive lung disease. 
 In Chapter 2 we examined the lung health of individuals in the SHS who 
previously had been treated for active tuberculosis in order assess the morbidity of 
nonmalignant respiratory effects when compared to those without a history of active 
tuberculosis. We used data from a medical record-based history of active tuberculosis, 
spirometric measures, and self-reported respiratory symptoms from the Visit 2 
examination (1993-1995) in 2,463 participants, adjusting for major lung health risk 
factors including smoking and cigarette pack-years. We also conducted a sub-analysis to 
examine the potential association between a history of active tuberculosis and arsenic 
exposure as well as a possible interaction between arsenic and tuberculosis on spirometric 
obstruction and restrictive patterns. In those with a history of active tuberculosis, lung 
function and respiratory symptoms were worse compared to those without active 
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tuberculosis, including a reduced FEV1 % predicted and FVC % predicted, and an 
increased odds of spirometric obstruction and restrictive pattern. A dose-response 
relationship was seen for decreasing lung function indices FEV1 % predicted and FVC % 
predicted in those with a history of active tuberculosis by increasing urinary arsenic 
concentrations, as expected, but elevated arsenic exposure was associated with a reduced 
odds of a past history of active tuberculosis, an unexpected finding. 
In Chapter 3 we conducted a water quality assessment in preparation for the 
Strong Heart Water Study (SHWS) intervention to identify households with private wells 
with elevated arsenic, using inductively coupled plasma mass spectrometry, that are 
eligible for the SHWS; assess water quality parameters that could interfere with the 
efficacy of the adsorptive media filter; evaluate the accuracy of a rapid testing kit for 
arsenic; and evaluate the efficacy of the adsorptive media filter. Water samples (n= 371) 
were collected from domestic wells between 2014 – 2018 in study communities where 
26.1% of households were found to have arsenic higher than 10 µg/L, with the majority 
of arsenic occurring as arsenate (As(V)). In 2015, a more detailed water quality 
assessment was conducted in a subset of households where rapid arsenic tests were used, 
and additional water quality parameters were examined for possible compounds that 
interfere with an arsenic filtration device. The rapid test kits were not sufficiently 
accurate in the study setting, and silica was found to be above the concentration for 
optimal filter performance. Finally, we evaluated the efficacy of an adsorptive media 
filter for its ability to remove As(V) at the kitchen sink in six households. After being 
monitored for nine months, the filters were found to reduce arsenic to below the limit of 





In Chapter 1, we observed a significant relationship between arsenic and 
spirometric obstruction only in former cigarette smokers, as compared to never and 
current smokers, which was not expected. As smoking is a major cause of lung 
obstruction, we anticipated that we would see the strongest effect estimates in current 
smokers. A small number of previous studies have reported similar findings, specifically 
examining lung function indicies,1, 2 with conjecture that active smoking’s toxic effects 
could be masking those of arsenic. Studies which have examined the interaction between 
smoking, arsenic, and lung cancer have generally found the presence of a synergistic 
interaction, that the excess risk resulting from the combination of exposure to smoking 
and arsenic is greater than the sum of excess risks from each exposure alone.3, 4 There is 
less known about nonmalignant lung disease outcomes; a recent meta-analysis found the 
association between arsenic and FVC to be slightly stronger among non-smokers than 
smokers, for reasons unknown.5 
Additionally, in Chapter 1, we did not find an association with lung function 
patterns and arsenic metabolism, which was unexpected as arsenic metabolism has been 
related to multiple health outcomes. After ingestion, arsenic is metabolized into mono- 
and di-methylated arsenicals (MMA and DMA).6 The methylation of inorganic arsenic to 
DMA facilitates its excretion and detoxification, with findings often showing that a 
higher percentages of DMA and lower MMA in the urine is associated with reduced 
arsenic-related health effects, including cardiovascular disease and cancer7 with some 
evidence of lung cancer.8, 9 Lung cancer studies have shown that individuals who are less 
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effective at methylating MMA to DMA are at increased risk of lung cancer at water 
arsenic exposure levels of <200 µg/L. While we expected to possibly see an indication of 
restrictive or obstructive spirometric pattern associated with arsenic methylation similar 
to that of what has been seen with lung cancer, the majority of individuals in the lung 
cancer studies were exposed to water arsenic concentrations much higher than 10 µg/L, 
and thus perhaps less comparable to the SHS population.8, 9 
In our additional analysis in Chapter 2, we found a statistically significant reduced 
odds of a past active tuberculosis diagnosis associated with arsenic exposure, which was 
unexpected. The finding is inconsistent with the one earlier study from Chile which also 
examined the relationship between tuberculosis and arsenic.10 This previous ecological 
study found increased mortality from pulmonary tuberculosis associated with arsenic 
levels in drinking water, with mortality rates increasing ten years after high arsenic 
exposure (870 µg/L) commenced. Our finding of a reduced odds of tuberculosis could be 
an effect of survival bias, as more severe tuberculosis cases may have resulted in 
mortalities prior to the start of the SHS; we could be over-representing those with long-
term survival after treatment for tuberculosis, particularly as advanced age, diabetes, and 
chronic obstructive pulmonary disease have been shown to be associated with an 
increased risk of death during tuberculosis treatment,11 risk factors very relevant to our 
cohort. We could not determine if arsenic could have increased the incidence of active 
tuberculosis or increased the mortality among those with tuberculosis, which could also 
spuriously result in an inverse association similar to the one that we observe. Even with 
our unexpected finding of reduced odds, we know to interpret it cautiously as both 
arsenic and tuberculosis are both known to be associated with an increased risk of 
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developing bronchiectasis. This suggests a potential common pathophysiology for the 
long-term impact of arsenic and tuberculosis on lung disease.12-14 This common 
pathophysiology can actually support the synergistic interaction we observed between 
past active tuberculosis and arsenic exposure on lung outcomes.  
In Chapter 3, our finding that a low-range field rapid arsenic testing kit had low 
accuracy and, therefore, not an option as a screening tool for the SHWS intervention was 
unexpected. As the same rapid testing kit had been found to be accurate in previous 
studies,15-20 the test was planned to be used as a way to help develop local expertise on 
testing water sources so that there would be long-term sustainability of arsenic water 
testing conducted by community members, especially as most private well users in these 
communities are unknowingly at risk of elevated arsenic exposure due to lack of access 
to water testing services. An original goal of the SHWS intervention was that the rapid 
test kit could be used by a field team with minimal training to accurately measure water 
arsenic levels rapidly, give feedback to family and enroll the households into the study if 
they were eligible. Due to its poor performance, the rapid test kit cannot be used as a 
screening tool for the SHWS. Instead, ICMPS, which is highly accurate and sensitive, 
was used as the sole method for arsenic detection. 
 
Strengths and Limitations 
 This dissertation benefitted from several strengths. The SHS is a well-established 
cohort with high-quality laboratory methods, high participant retention, consistent 
variable collection, careful outcomes determination, and strong support from the 
communities involved. We had individual spirometric measurements standardized to 
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American Thoracic Society recommendations. We also had American Indian reference 
values derived from the SHS cohort, which allowed for results to be evaluated for 
abnormalities against predicted values for better interpretation of results. However, the 
subgroup used to calculate predicted values, while comprehensive in excluding those 
with respiratory disease, symptoms, and comorbidities, did not exclude those individuals 
with high arsenic exposure. This is unlikely to be a major limitation as lung function 
measures across arsenic tertiles showed similar trends when using % predicted values vs. 
crude (mL) values (Chapter 1, Table 5). We were able to adjust models for the more 
prevalent and important risk factors for lung health, including smoking status and 
cigarette pack-year; however, these measures were self-reported as we did not have a 
biomarker of tobacco exposure. A strength was that we had the unique opportunity to 
apply our respiratory health findings from the SHS to the SHWS. The SHWS is the first 
study to evaluate the effectiveness of an intervention approach to reduce arsenic exposure 
in American Indian communities, so that we can ultimately examine respiratory health 
before and after installation of a point-of-use water arsenic filter. 
 As in all epidemiological studies, several limitations affected the results and 
interpretations of this thesis. In Chapter 3, our evaluation of the rapid arsenic testing kit 
was limited to a very small subset in the SHWS, making it difficult to make broad 
conclusions from our results and prohibiting external validity outside of our study 
communities in rural North Dakota and South Dakota. In Chapters 1 and 2, we lacked 
information on possible exposure to indoor air pollutants, including secondhand smoke 
and exposure to smoke from cooking fires or heating fuel, potentially important 
contributors to lung health were unadjusted for in models. Spirometry reliability could 
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have impacted our results. A measure of total lung capacity is recommended in clinical 
practice to diagnose restrictive lung disease. In lieu of this measurement, FVC is used in 
population-based epidemiological studies, and can result in low sensitivity and poor 
specificity in identifying restrictive patterns.21 There has been technological improvement 
in spirometric methodology, as the change in test session repeatability criteria has 
reduced from the 1994 level of <200 mL to <150 mL, per ATS/ERS standardization 
recommendations.22 Spirometric results from 1993-1995 in the SHS should be interpreted 
cautiously when comparing to any future spirometric results from the same population, 
considering they employed the then-current but comparatively more lenient repeatability 
requirement of 200 mL.23 The protocol for spirometric testing in the SHS did not include 
post-bronchodilator testing and we were not able to assess the change over time in lung 
function based on post-bronchodilator testing. While urine arsenic metabolites have been 
shown to be consistent over time,24 urine arsenic collected at multiple visits would have 
made our results more robust. Additionally, being able to examine spirometry at multiple 
visits would have made our analyses and interpretations stronger, as without longitudinal 
spirometric data, we were not able to determine the possible temporal relationship 
between arsenic exposure and lung disease. 
 
Implications and Future Research 
This dissertation provides novel evidence that exposure to low-moderate arsenic 
may have a deleterious effect on lung function, not examined before in any American 
Indian population. Studies evaluating the effect of low-level arsenic exposure are critical 
to assist in accurately characterizing the total health risk posed by arsenic, particularly as 
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some states in the US are reassessing exposure level standards in drinking water. 
Longitudinal studies of lung function and low-moderate arsenic are important to further 
examine the types of lung disease associated with arsenic exposure, the possible temporal 
relationship, and explore arsenic methylation as it relates to these outcomes. 
Our finding that a history of active tuberculosis is a risk factor for long-term 
respiratory impairment confirms existing knowledge, adds evidence of the relationship 
from an American Indian population which is lacking in the literature base, and adds 
information on specific spirometric disease patterns. Our unexpected finding of reduced 
odds of active tuberculosis associated with arsenic exposure warrants further research to 
better understand this relationship. In addition to tuberculosis, future research could 
examine whether higher arsenic exposure is associated with repeated respiratory 
infections and contribution to overall respiratory health. More common respiratory 
infections in American Indians include coccidioidomycosis, known as valley fever, which 
occurs due to the inhalation of fungi spores found in soil in desert regions of the 
Southwest, pneumonia, and Hemophilus influenzae.25 
Our finding of a high overall burden of spirometry-defined obstruction and 
restriction in the SHS is important as little has been known about the nonmalignant 
respiratory health in the population. Continued surveillance with spirometry is necessary 
for monitoring the respiratory health of the population, as morbidity for diseases like 
chronic obstructive pulmonary disorder is important to track, since these data can provide 
an estimate of the need for health services.26 Through the SHWS we have the opportunity 
to evaluate changes in lung function using spirometry with delivery of an intervention to 
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reduce arsenic exposure in SHS communities. This will greatly add to our understanding 
of the relationship between arsenic and respiratory health. 
An important finding from our water quality assessment in the SHWS was that 
arsenic above the current US health safety standard (>10 µg/L) in drinking water is 
relatively common in the study communities. This, combined with our epidemiological 
findings on lung health, support the need for interventions like the SHWS. The finding 
that the rapid arsenic test kits were not accurate in the study setting meant that study 
procedure had to be changed, but also confirmed that the SHWS intervention has reliable 
data on which households have elevated drinking water arsenic and are eligible to enroll 
in the study. 
 
Conclusions 
 Chronic lung disease is among the leading causes of death worldwide, making 
identification of modifiable risk factors, as well as high risk populations, a public health 
priority. Previous studies have reported water arsenic exposure to be associated with 
nonmalignant respiratory health; however, most studies have occurred at high arsenic 
exposure levels, with few examining exposure at low-moderate (<50 µg/L) arsenic levels. 
This dissertation adds evidence that low-moderate arsenic exposure from water is 
associated with reduced lung function and increased respiratory symptoms in an 
American Indian population. Further, we present evidence that a past history of active 
tuberculosis is associated with long-term pulmonary damage with suggestive evidence of 
a possible interaction between arsenic exposure and tuberculosis on lung function. This 
evidence combined with the finding of elevated arsenic being common in study 
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households, points to the need for prevention strategies like the SHWS intervention to 
protect human health at the household level. Furthermore, increased respiratory 
symptoms and reduced lung function from a history of tuberculosis or chronic arsenic 
exposure is likely contributing to an unmeasured burden of chronic lung disease. Added 
with the systemic underrepresentation of American Indians in published biomedical 
research on pulmonary disease, this indicates an urgent need for the continued monitoring 
of American Indian respiratory health and additional research to better understand the 
intersecting relationships between arsenic, tuberculosis and other respiratory infections, 
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